source: qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID@ 1508

Last change on this file since 1508 was 1508, checked in by Sam Habiel, 12 years ago

Semi-final patch 3

File size: 97.2 KB
Line 
1KIDS Distribution saved on Aug 03, 2012@17:09:59
2QUALITY MEASURES 1.0 PATCH 3
3**KIDS**:C0Q*1.0*3^
4
5**INSTALL NAME**
6C0Q*1.0*3
7"BLD",7936,0)
8C0Q*1.0*3^QUALITY MEASURES^0^3120803^y
9"BLD",7936,1,0)
10^^155^155^3120803^
11"BLD",7936,1,1,0)
12 Summary
13"BLD",7936,1,2,0)
14 =======
15"BLD",7936,1,3,0)
16 This build contains the Quality Measures file (#1130580001.101) fully
17"BLD",7936,1,4,0)
18 populated with the Reminder Rule Sets and if applicable Reminder Extract
19"BLD",7936,1,5,0)
20 definitions for use with the Quality Measures package for reporting for
21"BLD",7936,1,6,0)
22 Meaningful use Stage I.
23"BLD",7936,1,7,0)
24
25"BLD",7936,1,8,0)
26 Source, Copyright, & Licensing:
27"BLD",7936,1,9,0)
28 ===============================
29"BLD",7936,1,10,0)
30 This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew
31"BLD",7936,1,11,0)
32Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0
33"BLD",7936,1,12,0)
34patches 12 and 17. The build was produced in July 2012.
35"BLD",7936,1,13,0)
36 Copyright WorldVistA 2012.
37"BLD",7936,1,14,0)
38 Licensed under GPL version 2 or later. Find it here:
39"BLD",7936,1,15,0)
40http://www.gnu.org/licenses/gpl-2.0.html
41"BLD",7936,1,16,0)
42 Released through VISTA Forum.
43"BLD",7936,1,17,0)
44
45"BLD",7936,1,18,0)
46 Functionality:
47"BLD",7936,1,19,0)
48 ==============
49"BLD",7936,1,20,0)
50 This patch is a pure data patch. It only installs reference data in the
51"BLD",7936,1,21,0)
52C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package
53"BLD",7936,1,22,0)
54data (specifically rule sets and extracts) sent in C0Q*1.0*2.
55"BLD",7936,1,23,0)
56
57"BLD",7936,1,24,0)
58 Package Elements:
59"BLD",7936,1,25,0)
60 =================
61"BLD",7936,1,26,0)
62 This build transports entries in the C0Q QUALITY MEASURE file.
63"BLD",7936,1,27,0)
64
65"BLD",7936,1,28,0)
66 Routines:
67"BLD",7936,1,29,0)
68 =========
69"BLD",7936,1,30,0)
70 <None>
71"BLD",7936,1,31,0)
72
73"BLD",7936,1,32,0)
74 Documentation:
75"BLD",7936,1,33,0)
76 <None besides this KIDS description>
77"BLD",7936,1,34,0)
78
79"BLD",7936,1,35,0)
80 Test Sites:
81"BLD",7936,1,36,0)
82 ===========
83"BLD",7936,1,37,0)
84 <None>
85"BLD",7936,1,38,0)
86
87"BLD",7936,1,39,0)
88 Compliance:
89"BLD",7936,1,40,0)
90 ===========
91"BLD",7936,1,41,0)
92 This software complies with the VA MUMPS Programming Standards and
93"BLD",7936,1,42,0)
94 Conventions (version 3 April 2007).
95"BLD",7936,1,43,0)
96
97"BLD",7936,1,44,0)
98 Installation Instructions:
99"BLD",7936,1,45,0)
100 ==========================
101"BLD",7936,1,46,0)
102 Pre-installation:
103"BLD",7936,1,47,0)
104
105"BLD",7936,1,48,0)
106 Prerequisite patches: (both found on the trac server here:
107"BLD",7936,1,49,0)
108 https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/)
109"BLD",7936,1,50,0)
110 C0Q*1.0*2
111"BLD",7936,1,51,0)
112 QUALITY MEASURES 1.0
113"BLD",7936,1,52,0)
114
115"BLD",7936,1,53,0)
116 Users can remain on the system while this patch is installed.
117"BLD",7936,1,54,0)
118
119"BLD",7936,1,55,0)
120 Install Time - less than 1 minute.
121"BLD",7936,1,56,0)
122
123"BLD",7936,1,57,0)
124 1. LOAD TRANSPORT GLOBAL
125"BLD",7936,1,58,0)
126
127"BLD",7936,1,59,0)
128 Choose the PackMan message containing this patch and invoke the
129"BLD",7936,1,60,0)
130 INSTALL/CHECK MESSAGE PackMan option to unload the build, or
131"BLD",7936,1,61,0)
132 Use the Load a Distribution option in KIDS to load it from a
133"BLD",7936,1,62,0)
134 host file.
135"BLD",7936,1,63,0)
136
137"BLD",7936,1,64,0)
138 2. START UP KIDS
139"BLD",7936,1,65,0)
140
141"BLD",7936,1,66,0)
142 Start up the Kernel Installation and Distribution System Menu
143"BLD",7936,1,67,0)
144 [XPD MAIN]:
145"BLD",7936,1,68,0)
146
147"BLD",7936,1,69,0)
148 Edits and Distribution ...
149"BLD",7936,1,70,0)
150 Utilities ...
151"BLD",7936,1,71,0)
152 Installation ...
153"BLD",7936,1,72,0)
154
155"BLD",7936,1,73,0)
156 Select Kernel Installation & Distribution System Option: INStallation
157"BLD",7936,1,74,0)
158 ---
159"BLD",7936,1,75,0)
160 Load a Distribution
161"BLD",7936,1,76,0)
162 Print Transport Global
163"BLD",7936,1,77,0)
164 Compare Transport Global to Current System
165"BLD",7936,1,78,0)
166 Verify Checksums in Transport Global
167"BLD",7936,1,79,0)
168 Install Package(s)
169"BLD",7936,1,80,0)
170 Restart Install of Package(s)
171"BLD",7936,1,81,0)
172 Unload a Distribution
173"BLD",7936,1,82,0)
174 Backup a Transport Global
175"BLD",7936,1,83,0)
176
177"BLD",7936,1,84,0)
178 Select Installation Option:
179"BLD",7936,1,85,0)
180
181"BLD",7936,1,86,0)
182 3. Select Installation Option:
183"BLD",7936,1,87,0)
184
185"BLD",7936,1,88,0)
186 NOTE: The following are OPTIONAL - (When prompted for the INSTALL
187"BLD",7936,1,89,0)
188 NAME, enter C0Q*1.0*3):
189"BLD",7936,1,90,0)
190
191"BLD",7936,1,91,0)
192 a. Backup a Transport Global - This option will create a backup
193"BLD",7936,1,92,0)
194 message of any routines exported with this patch. It will not
195"BLD",7936,1,93,0)
196 backup any other changes such as DD's or templates.
197"BLD",7936,1,94,0)
198 b. Compare Transport Global to Current System - This option will
199"BLD",7936,1,95,0)
200 allow you to view all changes that will be made when this patch
201"BLD",7936,1,96,0)
202 is installed. It compares all components of this patch
203"BLD",7936,1,97,0)
204 (routines, DD's, templates, etc.).
205"BLD",7936,1,98,0)
206 c. Verify Checksums in Transport Global - This option will allow
207"BLD",7936,1,99,0)
208 you to ensure the integrity of the routines that are in the
209"BLD",7936,1,100,0)
210 transport global.
211"BLD",7936,1,101,0)
212
213"BLD",7936,1,102,0)
214 4. Select Installation Option: Install Package(s)
215"BLD",7936,1,103,0)
216
217"BLD",7936,1,104,0)
218 **This is the step to start the installation of this KIDS patch:
219"BLD",7936,1,105,0)
220
221"BLD",7936,1,106,0)
222 a. Choose the Install Package(s) option to start the patch install
223"BLD",7936,1,107,0)
224 and enter "C0Q*1.0*3" at the INSTALL NAME prompt.
225"BLD",7936,1,108,0)
226 b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of
227"BLD",7936,1,109,0)
228 Install? NO//' answer NO
229"BLD",7936,1,110,0)
230 c. When prompted 'Want KIDS to INHIBIT LOGONs during the install?
231"BLD",7936,1,111,0)
232 NO//' answer NO
233"BLD",7936,1,112,0)
234 d. When prompted 'Want to DISABLE Scheduled Options, Menu Options,
235"BLD",7936,1,113,0)
236 and Protocols? NO//' answer NO
237"BLD",7936,1,114,0)
238
239"BLD",7936,1,115,0)
240
241"BLD",7936,1,116,0)
242Here is an example installation log.
243"BLD",7936,1,117,0)
244Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded
245"BLD",7936,1,118,0)
246from Di
247"BLD",7936,1,119,0)
248stribution 8/3/12@16:32:30
249"BLD",7936,1,120,0)
250 => SDFGHJKL ;Created on Aug 03, 2012@16:31:28
251"BLD",7936,1,121,0)
252
253"BLD",7936,1,122,0)
254This Distribution was loaded on Aug 03, 2012@16:32:30 with header of
255"BLD",7936,1,123,0)
256 SDFGHJKL ;Created on Aug 03, 2012@16:31:28
257"BLD",7936,1,124,0)
258 It consisted of the following Install(s):
259"BLD",7936,1,125,0)
260 C0Q*1.0*3
261"BLD",7936,1,126,0)
262
263"BLD",7936,1,127,0)
264 Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK
265"BLD",7936,1,128,0)
266 No overlap found
267"BLD",7936,1,129,0)
268DEVICE: HOME// PHOME HOME PRINTER
269"BLD",7936,1,130,0)
270
271"BLD",7936,1,131,0)
272
273"BLD",7936,1,132,0)
274 Install Started for C0Q*1.0*3 :
275"BLD",7936,1,133,0)
276 Aug 03, 2012@16:35:24
277"BLD",7936,1,134,0)
278
279"BLD",7936,1,135,0)
280Build Distribution Date: Aug 03, 2012
281"BLD",7936,1,136,0)
282
283"BLD",7936,1,137,0)
284 Installing Routines:.
285"BLD",7936,1,138,0)
286 Aug 03, 2012@16:35:24
287"BLD",7936,1,139,0)
288
289"BLD",7936,1,140,0)
290 Installing Data Dictionaries: ..
291"BLD",7936,1,141,0)
292 Aug 03, 2012@16:35:24
293"BLD",7936,1,142,0)
294
295"BLD",7936,1,143,0)
296 Installing Data:
297"BLD",7936,1,144,0)
298 Aug 03, 2012@16:35:24
299"BLD",7936,1,145,0)
300
301"BLD",7936,1,146,0)
302 Updating Routine file.....
303"BLD",7936,1,147,0)
304
305"BLD",7936,1,148,0)
306 Updating KIDS files.......
307"BLD",7936,1,149,0)
308
309"BLD",7936,1,150,0)
310 C0Q*1.0*3 Installed.
311"BLD",7936,1,151,0)
312 Aug 03, 2012@16:35:24
313"BLD",7936,1,152,0)
314
315"BLD",7936,1,153,0)
316 Not a VA primary domain
317"BLD",7936,1,154,0)
318
319"BLD",7936,1,155,0)
320 NO Install Message sent
321"BLD",7936,4,0)
322^9.64PA^1130580001.101^1
323"BLD",7936,4,1130580001.101,0)
3241130580001.101
325"BLD",7936,4,1130580001.101,222)
326y^y^f^^y^^y^o^n
327"BLD",7936,4,"B",1130580001.101,1130580001.101)
328
329"BLD",7936,6.3)
33011
331"BLD",7936,"ABPKG")
332n
333"BLD",7936,"KRN",0)
334^9.67PA^779.2^20
335"BLD",7936,"KRN",.4,0)
336.4
337"BLD",7936,"KRN",.401,0)
338.401
339"BLD",7936,"KRN",.402,0)
340.402
341"BLD",7936,"KRN",.403,0)
342.403
343"BLD",7936,"KRN",.5,0)
344.5
345"BLD",7936,"KRN",.84,0)
346.84
347"BLD",7936,"KRN",3.6,0)
3483.6
349"BLD",7936,"KRN",3.8,0)
3503.8
351"BLD",7936,"KRN",9.2,0)
3529.2
353"BLD",7936,"KRN",9.8,0)
3549.8
355"BLD",7936,"KRN",19,0)
35619
357"BLD",7936,"KRN",19.1,0)
35819.1
359"BLD",7936,"KRN",101,0)
360101
361"BLD",7936,"KRN",409.61,0)
362409.61
363"BLD",7936,"KRN",771,0)
364771
365"BLD",7936,"KRN",779.2,0)
366779.2
367"BLD",7936,"KRN",870,0)
368870
369"BLD",7936,"KRN",8989.51,0)
3708989.51
371"BLD",7936,"KRN",8989.52,0)
3728989.52
373"BLD",7936,"KRN",8994,0)
3748994
375"BLD",7936,"KRN","B",.4,.4)
376
377"BLD",7936,"KRN","B",.401,.401)
378
379"BLD",7936,"KRN","B",.402,.402)
380
381"BLD",7936,"KRN","B",.403,.403)
382
383"BLD",7936,"KRN","B",.5,.5)
384
385"BLD",7936,"KRN","B",.84,.84)
386
387"BLD",7936,"KRN","B",3.6,3.6)
388
389"BLD",7936,"KRN","B",3.8,3.8)
390
391"BLD",7936,"KRN","B",9.2,9.2)
392
393"BLD",7936,"KRN","B",9.8,9.8)
394
395"BLD",7936,"KRN","B",19,19)
396
397"BLD",7936,"KRN","B",19.1,19.1)
398
399"BLD",7936,"KRN","B",101,101)
400
401"BLD",7936,"KRN","B",409.61,409.61)
402
403"BLD",7936,"KRN","B",771,771)
404
405"BLD",7936,"KRN","B",779.2,779.2)
406
407"BLD",7936,"KRN","B",870,870)
408
409"BLD",7936,"KRN","B",8989.51,8989.51)
410
411"BLD",7936,"KRN","B",8989.52,8989.52)
412
413"BLD",7936,"KRN","B",8994,8994)
414
415"BLD",7936,"QUES",0)
416^9.62^^
417"BLD",7936,"REQB",0)
418^9.611^2^2
419"BLD",7936,"REQB",1,0)
420C0Q*1.0*2^2
421"BLD",7936,"REQB",2,0)
422QUALITY MEASURES 1.0^2
423"BLD",7936,"REQB","B","C0Q*1.0*2",1)
424
425"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
426
427"DATA",1130580001.101,4,0)
428PQRI MEASURE 124^^^2.16.840.1.113883.3.249.11.11
429"DATA",1130580001.101,4,1)
430Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
431"DATA",1130580001.101,4,4)
432PQRI-124
433"DATA",1130580001.101,4,5)
434Adoption/Use of Electronic Health Records (EHR)
435"DATA",1130580001.101,4,6,0)
436^^3^3^3101013^
437"DATA",1130580001.101,4,6,1,0)
438Documents whether provider has adopted and is using health inf
439"DATA",1130580001.101,4,6,2,0)
440ormation technology. To qualify, the provider must havea adopted and be
441"DATA",1130580001.101,4,6,3,0)
442using a certified/qualified electronic health record (EHR)
443"DATA",1130580001.101,4,7)
444^^^^
445"DATA",1130580001.101,6,0)
446PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52
447"DATA",1130580001.101,6,1)
448Measure #47: Advance Care Plan
449"DATA",1130580001.101,6,4)
450PQRI-47
451"DATA",1130580001.101,6,5)
452Advance Care Plan
453"DATA",1130580001.101,6,6,0)
454^1130580001.111^5^5^3101014^^^
455"DATA",1130580001.101,6,6,1,0)
456Percentage of patients age 65 and older who have an advanced care plan or
457"DATA",1130580001.101,6,6,2,0)
458surrogate decision maker documented in the medical record or documented
459"DATA",1130580001.101,6,6,3,0)
460in the medical record that an advance care plan was discussed but the
461"DATA",1130580001.101,6,6,4,0)
462patient did not wish or was not able to name a surrogate decision maker
463"DATA",1130580001.101,6,6,5,0)
464or provide an advance care plan.
465"DATA",1130580001.101,6,7)
466^^^^
467"DATA",1130580001.101,7,0)
468PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53
469"DATA",1130580001.101,7,1)
470Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
471"DATA",1130580001.101,7,4)
472PQRI-48
473"DATA",1130580001.101,7,5)
474Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
475"DATA",1130580001.101,7,6,0)
476^^3^3^3101013^
477"DATA",1130580001.101,7,6,1,0)
478Percentage of patients equal to or older than 65 years of age at the
479"DATA",1130580001.101,7,6,2,0)
480beginning of the measurement perion who were assesed for the presence or
481"DATA",1130580001.101,7,6,3,0)
482absence of urinary incontinence within 12 months
483"DATA",1130580001.101,7,7)
484^^^^
485"DATA",1130580001.101,12,0)
486MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8
487"DATA",1130580001.101,12,1)
488Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
489"DATA",1130580001.101,12,4)
490PQRI-111
491"DATA",1130580001.101,12,5)
492Pneumonia Vaccination for Patients 65 Years and Older
493"DATA",1130580001.101,12,6,0)
494^1130580001.111^2^2^3120730^^
495"DATA",1130580001.101,12,6,1,0)
496Percentage of patients afed 65 years and older who have ever r
497"DATA",1130580001.101,12,6,2,0)
498eceived a pneumoccal vaccine
499"DATA",1130580001.101,12,7)
500NQF0043
501"DATA",1130580001.101,14,0)
502PQRI MEASURE 39^^^2.16.840.1.113883.3.249.11.51
503"DATA",1130580001.101,14,1)
504Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
505"DATA",1130580001.101,14,4)
506PQRI-39
507"DATA",1130580001.101,14,5)
508Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
509"DATA",1130580001.101,14,6,0)
510^^3^3^3101013^
511"DATA",1130580001.101,14,6,1,0)
512Percentage of patients who had a DXA measurement ordered or pe
513"DATA",1130580001.101,14,6,2,0)
514rformed at least once since age 60 or pharmacologic therapy prescribed
515"DATA",1130580001.101,14,6,3,0)
516within 12 months before the end of the measurement period
517"DATA",1130580001.101,14,7)
518^^^^
519"DATA",1130580001.101,16,0)
520PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55
521"DATA",1130580001.101,16,1)
522Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
523"DATA",1130580001.101,16,4)
524PQRI-173
525"DATA",1130580001.101,16,5)
526Preventive Care and Screening: Unhealthy Alcohol Use - Screening
527"DATA",1130580001.101,16,6,0)
528^^2^2^3101013^
529"DATA",1130580001.101,16,6,1,0)
530Percentage of patients aged 18 years and older who were screen
531"DATA",1130580001.101,16,6,2,0)
532ed for unhealthy alcohol use using a systematic method within 24 months
533"DATA",1130580001.101,16,7)
534^^^^
535"DATA",1130580001.101,23,0)
536MU HOS NQF 0495^^
537"DATA",1130580001.101,23,1)
538ED THROUGHPUT ARRIVAL TO DEPARTURE
539"DATA",1130580001.101,23,5)
540ED THROUGHPUT ARRIVAL TO DEPARTURE
541"DATA",1130580001.101,23,6,0)
542^1130580001.111^3^3^3110430^^^^
543"DATA",1130580001.101,23,6,1,0)
544Median time from emergency department arrival to time of departure from
545"DATA",1130580001.101,23,6,2,0)
546the emergency room for patients admitted to the facility from the
547"DATA",1130580001.101,23,6,3,0)
548emergency department
549"DATA",1130580001.101,23,7)
550NQF0495^^^^^^88^165
551"DATA",1130580001.101,24,0)
552MU HOS NQF 0497^^
553"DATA",1130580001.101,24,1)
554ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
555"DATA",1130580001.101,24,5)
556ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
557"DATA",1130580001.101,24,6,0)
558^^3^3^3110430^
559"DATA",1130580001.101,24,6,1,0)
560Median time from admit decision time to time of departure from the
561"DATA",1130580001.101,24,6,2,0)
562emergency department of emergency department patients admitted to
563"DATA",1130580001.101,24,6,3,0)
564inpatient status
565"DATA",1130580001.101,24,7)
566NQF0497^^^^^^90^168
567"DATA",1130580001.101,25,0)
568MU HOS NQF 0435^^
569"DATA",1130580001.101,25,1)
570Ischemic stroke.Discharge on anti-thrombotics
571"DATA",1130580001.101,25,5)
572 Ischemic stroke.Discharge on anti-thrombotic
573"DATA",1130580001.101,25,6,0)
574^^2^2^3110430^
575"DATA",1130580001.101,25,6,1,0)
576Ischemic stroke patients prescribed antithrombotic therapy at hospital
577"DATA",1130580001.101,25,6,2,0)
578discharge
579"DATA",1130580001.101,25,7)
580NQF0435^^^^^^114^115
581"DATA",1130580001.101,26,0)
582MU HOS NQF 0436^^
583"DATA",1130580001.101,26,1)
584 Ischemic stroke.Anticoagulation for A-fib/flutter
585"DATA",1130580001.101,26,5)
586Ischemic stroke.Anticoagulation for A-fib/flutter
587"DATA",1130580001.101,26,6,0)
588^1130580001.111^2^2^3110430^^^
589"DATA",1130580001.101,26,6,1,0)
590 Ischemic stroke patients with atrial fibrillation/flutter who are
591"DATA",1130580001.101,26,6,2,0)
592prescribed anticoagulation therapy at hospital discharge
593"DATA",1130580001.101,26,7)
594NQF0436^^^^^^116^117
595"DATA",1130580001.101,27,0)
596MU HOS NQF 0437^^
597"DATA",1130580001.101,27,1)
598 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
599"DATA",1130580001.101,27,5)
600Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
601"DATA",1130580001.101,27,6,0)
602^^3^3^3110430^
603"DATA",1130580001.101,27,6,1,0)
604Acute ischemic stroke patients who arrive at this hospital within 2
605"DATA",1130580001.101,27,6,2,0)
606hours of time last known well and for whom IV t-PA was initiated at this
607"DATA",1130580001.101,27,6,3,0)
608hospital within 3 hours of time last known well.
609"DATA",1130580001.101,27,7)
610NQF0437^^^^^^119^118
611"DATA",1130580001.101,28,0)
612MU HOS NQF 0438^^
613"DATA",1130580001.101,28,1)
614Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
615"DATA",1130580001.101,28,5)
616Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
617"DATA",1130580001.101,28,6,0)
618^^2^2^3110430^
619"DATA",1130580001.101,28,6,1,0)
620Ischemic stroke patients administered antithrombotic therapy by the
621"DATA",1130580001.101,28,6,2,0)
622end of hospital day 2.
623"DATA",1130580001.101,28,7)
624NQF0438^^^^^^120^121
625"DATA",1130580001.101,29,0)
626MU HOS NQF 0439^^
627"DATA",1130580001.101,29,1)
628Ischemic stroke.Discharge on statins
629"DATA",1130580001.101,29,5)
630Ischemic stroke.Discharge on statins
631"DATA",1130580001.101,29,6,0)
632^^3^3^3110430^
633"DATA",1130580001.101,29,6,1,0)
634Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
635"DATA",1130580001.101,29,6,2,0)
636who were on a lipid-lowering medication prior to hospital arrival are
637"DATA",1130580001.101,29,6,3,0)
638prescribed statin medication at hospital discharge
639"DATA",1130580001.101,29,7)
640NQF0439^^^^^^122^123
641"DATA",1130580001.101,30,0)
642MU HOS NQF 0440^^
643"DATA",1130580001.101,30,1)
644Ischemic or hemorrhagic stroke.Stroke education
645"DATA",1130580001.101,30,5)
646Ischemic or hemorrhagic stroke.Stroke education
647"DATA",1130580001.101,30,6,0)
648^^5^5^3110430^
649"DATA",1130580001.101,30,6,1,0)
650Ischemic or hemorrhagic stroke patients or their caregivers who were
651"DATA",1130580001.101,30,6,2,0)
652given educational materials during the hospital stay addressing all of the
653"DATA",1130580001.101,30,6,3,0)
654following: activation of emergency medical system, need for follow-up
655"DATA",1130580001.101,30,6,4,0)
656after discharge, medications prescribed at discharge, risk factors for
657"DATA",1130580001.101,30,6,5,0)
658stroke, and warning signs and symptoms of stroke.
659"DATA",1130580001.101,30,7)
660NQF0440^^^^^^124^125
661"DATA",1130580001.101,31,0)
662MU HOS NQF 0441^^
663"DATA",1130580001.101,31,1)
664Ischemic or hemorrhagic stroke.Rehabilitation assessment
665"DATA",1130580001.101,31,5)
666Ischemic or hemorrhagic stroke.Rehabilitation assessment
667"DATA",1130580001.101,31,6,0)
668^^2^2^3110430^
669"DATA",1130580001.101,31,6,1,0)
670Ischemic or hemorrhagic stroke patients who were assessed for
671"DATA",1130580001.101,31,6,2,0)
672rehabilitation services.
673"DATA",1130580001.101,31,7)
674NQF0441^^^^^^126^127
675"DATA",1130580001.101,32,0)
676MU HOS NQF 0371^^
677"DATA",1130580001.101,32,1)
678VTE prophylaxis within 24 hours of arrival
679"DATA",1130580001.101,32,5)
680VTE prophylaxis within 24 hours of arrival
681"DATA",1130580001.101,32,6,0)
682^^4^4^3110430^
683"DATA",1130580001.101,32,6,1,0)
684This measure assesses the number of patients who received VTE prophylaxis
685"DATA",1130580001.101,32,6,2,0)
686or have documentation why no VTE prophylaxis was given the day of or the
687"DATA",1130580001.101,32,6,3,0)
688day after hospital admission or surgery end date for surgeries that start
689"DATA",1130580001.101,32,6,4,0)
690the day of or the day after hospital admission.
691"DATA",1130580001.101,32,7)
692NQF0371^^^^^^69^67
693"DATA",1130580001.101,33,0)
694MU HOS NQF 0372^^
695"DATA",1130580001.101,33,1)
696ICU VTE prophylaxis
697"DATA",1130580001.101,33,5)
698ICU VTE prophylaxis
699"DATA",1130580001.101,33,6,0)
700^^5^5^3110430^
701"DATA",1130580001.101,33,6,1,0)
702This measure assesses the number of patients who received VTE prophylaxis
703"DATA",1130580001.101,33,6,2,0)
704or have documentation why no VTE prophylaxis was given the day of or the
705"DATA",1130580001.101,33,6,3,0)
706day after the initial admission (or transfer) to the Intensive Care Unit
707"DATA",1130580001.101,33,6,4,0)
708(ICU) or surgery end date for surgeries that start the day of or the day
709"DATA",1130580001.101,33,6,5,0)
710after ICU admission (or transfer).
711"DATA",1130580001.101,33,7)
712NQF0372^^^^^^128^71
713"DATA",1130580001.101,34,0)
714MU HOS NQF 0373^^
715"DATA",1130580001.101,34,1)
716Anticoagulation overlap therapy
717"DATA",1130580001.101,34,5)
718Anticoagulation overlap therapy
719"DATA",1130580001.101,34,6,0)
720^^8^8^3110430^
721"DATA",1130580001.101,34,6,1,0)
722This measure assesses the number of patients diagnosed with confirmed VTE
723"DATA",1130580001.101,34,6,2,0)
724who received an overlap of parenteral (intravenous [IV] or subcutaneous
725"DATA",1130580001.101,34,6,3,0)
726[subcu]) anticoagulation and warfarin therapy. For patients who received
727"DATA",1130580001.101,34,6,4,0)
728less than five days of overlap therapy, they must be discharged on both
729"DATA",1130580001.101,34,6,5,0)
730medications. Overlap therapy must be administered for at least five days
731"DATA",1130580001.101,34,6,6,0)
732with an international normalized ratio (INR) . 2 prior to discontinuation
733"DATA",1130580001.101,34,6,7,0)
734of the parenteral anticoagulation therapy or the patient must be
735"DATA",1130580001.101,34,6,8,0)
736discharged on both medications.
737"DATA",1130580001.101,34,7)
738NQF0373^^^^^^129^144
739"DATA",1130580001.101,35,0)
740MU HOS NQF 0374^^
741"DATA",1130580001.101,35,1)
742Platelet monitoring on unfractionated heparin
743"DATA",1130580001.101,35,5)
744Platelet monitoring on unfractionated heparin
745"DATA",1130580001.101,35,6,0)
746^^10^10^3110430^
747"DATA",1130580001.101,35,6,1,0)
748This measure assesses the number of patients diagnosed with confirmed VTE
749"DATA",1130580001.101,35,6,2,0)
750who received intravenous (IV) UFH therapy dosages AND had their platelet
751"DATA",1130580001.101,35,6,3,0)
752counts monitored using defined parameters such as a nomogram or
753"DATA",1130580001.101,35,6,4,0)
754protocol This measure assesses the number of patients diagnosed with
755"DATA",1130580001.101,35,6,5,0)
756confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
757"DATA",1130580001.101,35,6,6,0)
758their platelet counts monitored using defined parameters such as a
759"DATA",1130580001.101,35,6,7,0)
760nomogram or protocol This measure assesses the number of patients
761"DATA",1130580001.101,35,6,8,0)
762diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
763"DATA",1130580001.101,35,6,9,0)
764dosages AND had their platelet counts monitored using defined parameters
765"DATA",1130580001.101,35,6,10,0)
766such as a nomogram or protocol
767"DATA",1130580001.101,35,7)
768NQF0374^^^^^^145^146
769"DATA",1130580001.101,36,0)
770MU HOS NQF 0375^^
771"DATA",1130580001.101,36,1)
772VTE discharge instructions
773"DATA",1130580001.101,36,5)
774VTE discharge instructions
775"DATA",1130580001.101,36,6,0)
776^^11^11^3110430^
777"DATA",1130580001.101,36,6,1,0)
778This measure assesses the number of patients diagnosed with confirmed VTE
779"DATA",1130580001.101,36,6,2,0)
780that are discharged to home, to home with home health, home hospice or
781"DATA",1130580001.101,36,6,3,0)
782discharged/transferred to court/law enforcement on warfarin with written
783"DATA",1130580001.101,36,6,4,0)
784discharge instructions that address all four criteria: compliance issues,
785"DATA",1130580001.101,36,6,5,0)
786dietary advice, follow-up This measure assesses the number of patients
787"DATA",1130580001.101,36,6,6,0)
788diagnosed with confirmed VTE that are discharged to home, to home with
789"DATA",1130580001.101,36,6,7,0)
790home health, home hospice or discharged/transferred to court/law
791"DATA",1130580001.101,36,6,8,0)
792enforcement on warfarin with written discharge instructions that address
793"DATA",1130580001.101,36,6,9,0)
794all four criteria: compliance issues, dietary advice, follow-up
795"DATA",1130580001.101,36,6,10,0)
796monitoring, and information about the potential for adverse drug
797"DATA",1130580001.101,36,6,11,0)
798reactions/interactions.
799"DATA",1130580001.101,36,7)
800NQF0375^^^^^^147^156
801"DATA",1130580001.101,37,0)
802MU HOS NQF 0376^^
803"DATA",1130580001.101,37,1)
804Incidence of potentially preventable VTE
805"DATA",1130580001.101,37,5)
806Incidence of potentially preventable VTE
807"DATA",1130580001.101,37,6,0)
808^^4^4^3110430^
809"DATA",1130580001.101,37,6,1,0)
810This measure assesses the number of patients diagnosed with confirmed VTE
811"DATA",1130580001.101,37,6,2,0)
812during hospitalization (not present on arrival) who did not receive VTE
813"DATA",1130580001.101,37,6,3,0)
814prophylaxis between hospital admission and the day before the VTE
815"DATA",1130580001.101,37,6,4,0)
816diagnostic testing order date.
817"DATA",1130580001.101,37,7)
818NQF0376^^^^^^158^162
819"DATA",1130580001.101,39,0)
820MU EP NQF 0421^^^2.16.840.1.113883.3.249.11.54
821"DATA",1130580001.101,39,1)
822NQF0421 Adult Weight Screening and Follow-Up
823"DATA",1130580001.101,39,4)
824PQRI-128
825"DATA",1130580001.101,39,5)
826NQF0421 Adult Weight Screening and Follow-Up
827"DATA",1130580001.101,39,6,0)
828^1130580001.111^6^6^3110628^^^^
829"DATA",1130580001.101,39,6,1,0)
830Percentage of patients aged 18
831"DATA",1130580001.101,39,6,2,0)
832years and older with a calculated BMI in the past
833"DATA",1130580001.101,39,6,3,0)
834six months or during the current visit documented in
835"DATA",1130580001.101,39,6,4,0)
836the medical record AND if the most recent BMI is
837"DATA",1130580001.101,39,6,5,0)
838outside parameters, a follow-up plan is
839"DATA",1130580001.101,39,6,6,0)
840documented.
841"DATA",1130580001.101,39,7)
842NQF0421^^^^^^321^320^10
843"DATA",1130580001.101,40,0)
844MU EP NQF 0013^^^2.16.840.1.113883.3.249.11.56
845"DATA",1130580001.101,40,1)
846NQF0013 Hypertension: Blood Pressure Measurement
847"DATA",1130580001.101,40,4)
848PQRI-13
849"DATA",1130580001.101,40,5)
850NQF0013 Hypertension: Blood Pressure Measurement
851"DATA",1130580001.101,40,6,0)
852^1130580001.111^4^4^3110628^^
853"DATA",1130580001.101,40,6,1,0)
854Percentage of patient visits for patients
855"DATA",1130580001.101,40,6,2,0)
856aged 18 years and older with a diagnosis of hypertension
857"DATA",1130580001.101,40,6,3,0)
858who have been seen for at least 2 office visits, with blood
859"DATA",1130580001.101,40,6,4,0)
860pressure (BP) recorded
861"DATA",1130580001.101,40,7)
862NQF0013^^^^^^142^167
863"DATA",1130580001.101,41,0)
864MU EP NQF 0028A^^^2.16.840.1.113883.3.249.11.59
865"DATA",1130580001.101,41,1)
866NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
867"DATA",1130580001.101,41,4)
868PQRI-28
869"DATA",1130580001.101,41,5)
870NQF0028A Tobacco Use Assessment
871"DATA",1130580001.101,41,6,0)
872^1130580001.111^7^7^3110625^^^
873"DATA",1130580001.101,41,6,1,0)
874 Percentage of patients aged 18 years and
875"DATA",1130580001.101,41,6,2,0)
876older who have been seen for at least 2 office visits who
877"DATA",1130580001.101,41,6,3,0)
878were queried about tobacco use one or more times within
879"DATA",1130580001.101,41,6,4,0)
88024 months b. Percentage of patients aged 18 years and
881"DATA",1130580001.101,41,6,5,0)
882older identified as tobacco users within the past 24
883"DATA",1130580001.101,41,6,6,0)
884months and have been seen for at least 2 office visits,
885"DATA",1130580001.101,41,6,7,0)
886who received cessation intervention.
887"DATA",1130580001.101,41,7)
888NQF0028A^^^^^^157^160
889"DATA",1130580001.101,42,0)
890MU EP NQF 0041^^^2.16.840.1.113883.3.249.11.7
891"DATA",1130580001.101,42,1)
892Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
893"DATA",1130580001.101,42,4)
894PQRI-110
895"DATA",1130580001.101,42,5)
896NQF0041 Influenza Immunization 50 years and older
897"DATA",1130580001.101,42,6,0)
898^^4^4^3110430^
899"DATA",1130580001.101,42,6,1,0)
900Percentage of patients aged 50 years
901"DATA",1130580001.101,42,6,2,0)
902and older who received an influenza immunization
903"DATA",1130580001.101,42,6,3,0)
904during the flu season (September through
905"DATA",1130580001.101,42,6,4,0)
906February).
907"DATA",1130580001.101,42,7)
908NQF0041^^^^^^242^243
909"DATA",1130580001.101,43,0)
910MU EP NQF 0024^^
911"DATA",1130580001.101,43,1)
912NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL)
913"DATA",1130580001.101,43,5)
914NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL)
915"DATA",1130580001.101,43,6,0)
916^^6^6^3120803^
917"DATA",1130580001.101,43,6,1,0)
918Percentage of patients 2 -17 years of age
919"DATA",1130580001.101,43,6,2,0)
920who had an outpatient visit with a Primary Care Physician
921"DATA",1130580001.101,43,6,3,0)
922(PCP) or OB/GYN and who had evidence of BMI
923"DATA",1130580001.101,43,6,4,0)
924percentile documentation, counseling for nutrition and
925"DATA",1130580001.101,43,6,5,0)
926counseling for physical activity during the measurement
927"DATA",1130580001.101,43,6,6,0)
928year. This specific Quality Measure is for all the children.
929"DATA",1130580001.101,43,7)
930NQF0024 ALL^^^^^^151^149
931"DATA",1130580001.101,44,0)
932MU EP NQF 0038^^^2.16.840.1.113883.3.249.11.60
933"DATA",1130580001.101,44,1)
934Childhood Immunization Status
935"DATA",1130580001.101,44,4)
936PQRI-38
937"DATA",1130580001.101,44,5)
938Childhood Immunization Status
939"DATA",1130580001.101,44,6,0)
940^^14^14^3110430^
941"DATA",1130580001.101,44,6,1,0)
942Percentage of children 2 years of age who
943"DATA",1130580001.101,44,6,2,0)
944had four diphtheria, tetanus and acellular pertussis
945"DATA",1130580001.101,44,6,3,0)
946(DTaP); three polio(IPV), one measles, ,mumps and
947"DATA",1130580001.101,44,6,4,0)
948rubella (MMR); two H influenza type B (HiB); three
949"DATA",1130580001.101,44,6,5,0)
950Percentage of children 2 years of age who
951"DATA",1130580001.101,44,6,6,0)
952had four diphtheria, tetanus and acellular pertussis
953"DATA",1130580001.101,44,6,7,0)
954(DTaP); three polio(IPV), one measles, ,mumps and
955"DATA",1130580001.101,44,6,8,0)
956rubella (MMR); two H influenza type B (HiB); three
957"DATA",1130580001.101,44,6,9,0)
958hepatitis B (Hep B); one chicken pox (VZV); four
959"DATA",1130580001.101,44,6,10,0)
960pneumococcal conjugate (PCV); two hepatitis A (Hep A);
961"DATA",1130580001.101,44,6,11,0)
962two or three rotavirus (RV); and two influenza (flu)
963"DATA",1130580001.101,44,6,12,0)
964vaccines by their second birthday. The measure
965"DATA",1130580001.101,44,6,13,0)
966calculates a rate for each vaccine and nine separate
967"DATA",1130580001.101,44,6,14,0)
968combination rates.
969"DATA",1130580001.101,44,7)
970NQF0038^^^^
971"DATA",1130580001.101,45,0)
972MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2
973"DATA",1130580001.101,45,1)
974Diabetes: Hemoglobin A1c Poor Contro
975"DATA",1130580001.101,45,4)
976PQRI-1
977"DATA",1130580001.101,45,5)
978Diabetes: NQF0059 Hemoglobin A1c Poor Control
979"DATA",1130580001.101,45,6,0)
980^^2^2^3110430^
981"DATA",1130580001.101,45,6,1,0)
982Percentage of patients 18 - 75 years of age with diabetes (type 1
983"DATA",1130580001.101,45,6,2,0)
984or type 2) who had hemoglobin A1c > 9.0%.
985"DATA",1130580001.101,45,7)
986NQF0059^^^^^^260^258
987"DATA",1130580001.101,46,0)
988MU EP NQF 0064^^^2.16.840.1.113883.3.249.11.3
989"DATA",1130580001.101,46,1)
990Diabetes: Low Density Lipoprotein (LDL) Management and Control
991"DATA",1130580001.101,46,4)
992PQRI-2
993"DATA",1130580001.101,46,5)
994NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
995"DATA",1130580001.101,46,6,0)
996^^3^3^3110430^
997"DATA",1130580001.101,46,6,1,0)
998Percentage of patients 18-75 years of age with diabetes (type 1
999"DATA",1130580001.101,46,6,2,0)
1000or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
1001"DATA",1130580001.101,46,6,3,0)
1002of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
1003"DATA",1130580001.101,46,7)
1004NQF0064^^^^^^248^258
1005"DATA",1130580001.101,47,0)
1006MU EP NQF 0061^^^2.16.840.1.113883.3.249.11.4
1007"DATA",1130580001.101,47,1)
1008Blood Pressure Management
1009"DATA",1130580001.101,47,4)
1010PQRI-3
1011"DATA",1130580001.101,47,5)
1012NQF0061 Diabetes: Blood Pressure Management
1013"DATA",1130580001.101,47,6,0)
1014^^2^2^3110430^
1015"DATA",1130580001.101,47,6,1,0)
1016Percentage of patients 18 - 75 years of age with
1017"DATA",1130580001.101,47,6,2,0)
1018diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
1019"DATA",1130580001.101,47,7)
1020NQF0061^^^^^^262^258
1021"DATA",1130580001.101,48,0)
1022MU EP NQF 0081^^^2.16.840.1.113883.3.249.11.5
1023"DATA",1130580001.101,48,1)
1024Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1025"DATA",1130580001.101,48,4)
1026PQRI-5
1027"DATA",1130580001.101,48,5)
1028Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1029"DATA",1130580001.101,48,6,0)
1030^^3^3^3110430^
1031"DATA",1130580001.101,48,6,1,0)
1032Percentage of patients aged 18 years and older with a
1033"DATA",1130580001.101,48,6,2,0)
1034diagnosis of heart failure and LVSD (LVEF < 40%) who were
1035"DATA",1130580001.101,48,6,3,0)
1036prescribed ACE inhibitor or ARB therapy
1037"DATA",1130580001.101,48,7)
1038NQF0081^^^^
1039"DATA",1130580001.101,49,0)
1040MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6
1041"DATA",1130580001.101,49,1)
1042CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
1043"DATA",1130580001.101,49,4)
1044PQRI-7
1045"DATA",1130580001.101,49,5)
1046Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
1047"DATA",1130580001.101,49,6,0)
1048^^3^3^3101013^
1049"DATA",1130580001.101,49,6,1,0)
1050Percentage of patients aged 18 years and older with a diagnosis of
1051"DATA",1130580001.101,49,6,2,0)
1052coronary artery disease and a prior MI who where prescribed beta-blocker
1053"DATA",1130580001.101,49,6,3,0)
1054therapy
1055"DATA",1130580001.101,49,7)
1056NQF0070
1057"DATA",1130580001.101,50,0)
1058MU EP NQF 0031^^^2.16.840.1.113883.3.249.11.9
1059"DATA",1130580001.101,50,1)
1060Breast Cancer Screening
1061"DATA",1130580001.101,50,4)
1062PQRI-112
1063"DATA",1130580001.101,50,5)
1064Breast Cancer Screening
1065"DATA",1130580001.101,50,6,0)
1066^^2^2^3110430^
1067"DATA",1130580001.101,50,6,1,0)
1068Percentage of women 40-69 years of age who had a
1069"DATA",1130580001.101,50,6,2,0)
1070mammogram to screen for breast cancer
1071"DATA",1130580001.101,50,7)
1072NQF0031^^^^
1073"DATA",1130580001.101,51,0)
1074MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10
1075"DATA",1130580001.101,51,1)
1076Colorectal Cancer Screening
1077"DATA",1130580001.101,51,4)
1078PQRI-113
1079"DATA",1130580001.101,51,5)
1080Colorectal Cancer Screening
1081"DATA",1130580001.101,51,6,0)
1082^^2^2^3110430^
1083"DATA",1130580001.101,51,6,1,0)
1084Percentage of adults 50-75 years of age who had appropriate screening for
1085"DATA",1130580001.101,51,6,2,0)
1086colorectal cancer.
1087"DATA",1130580001.101,51,7)
1088NQF0034^^^^
1089"DATA",1130580001.101,52,0)
1090MU EP NQF 0067^^
1091"DATA",1130580001.101,52,1)
1092Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1093"DATA",1130580001.101,52,5)
1094Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1095"DATA",1130580001.101,52,6,0)
1096^^2^2^3110430^
1097"DATA",1130580001.101,52,6,1,0)
1098Percentage of patients aged 18 years and older with a
1099"DATA",1130580001.101,52,6,2,0)
1100diagnosis of CAD who were prescribed oral antiplatelet therapy.
1101"DATA",1130580001.101,52,7)
1102NQF0067^^^^
1103"DATA",1130580001.101,53,0)
1104MU EP NQF 0083^^
1105"DATA",1130580001.101,53,1)
1106Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1107"DATA",1130580001.101,53,5)
1108Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1109"DATA",1130580001.101,53,6,0)
1110^^3^3^3110430^
1111"DATA",1130580001.101,53,6,1,0)
1112Percentage of patients aged 18 years and older with a
1113"DATA",1130580001.101,53,6,2,0)
1114diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
1115"DATA",1130580001.101,53,6,3,0)
1116prescribed beta-blocker therapy
1117"DATA",1130580001.101,53,7)
1118NQF0083^^^^
1119"DATA",1130580001.101,54,0)
1120MU EP NQF 0105^^
1121"DATA",1130580001.101,54,1)
1122Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1123"DATA",1130580001.101,54,5)
1124Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1125"DATA",1130580001.101,54,6,0)
1126^^4^4^3110430^
1127"DATA",1130580001.101,54,6,1,0)
1128The percentage of patients 18 years of age and older
1129"DATA",1130580001.101,54,6,2,0)
1130who were diagnosed with a new episode of major depression, treated
1131"DATA",1130580001.101,54,6,3,0)
1132with antidepressant medication, and who remained on an
1133"DATA",1130580001.101,54,6,4,0)
1134antidepressant medication treatment.
1135"DATA",1130580001.101,54,7)
1136NQF0105^^^^
1137"DATA",1130580001.101,55,0)
1138MU EP NQF 0086^^
1139"DATA",1130580001.101,55,1)
1140Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1141"DATA",1130580001.101,55,5)
1142Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1143"DATA",1130580001.101,55,6,0)
1144^^4^4^3110430^
1145"DATA",1130580001.101,55,6,1,0)
1146Percentage of patients aged 18 years and older with a
1147"DATA",1130580001.101,55,6,2,0)
1148diagnosis of POAG who have been seen for at least two office visits
1149"DATA",1130580001.101,55,6,3,0)
1150who have an optic nerve head evaluation during one or more office
1151"DATA",1130580001.101,55,6,4,0)
1152visits within 12 months.
1153"DATA",1130580001.101,55,7)
1154NQF0086^^^^
1155"DATA",1130580001.101,56,0)
1156MU EP NQF 0088^^
1157"DATA",1130580001.101,56,1)
1158Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1159"DATA",1130580001.101,56,5)
1160Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1161"DATA",1130580001.101,56,6,0)
1162^^5^5^3110430^
1163"DATA",1130580001.101,56,6,1,0)
1164Percentage of patients aged 18 years and older with a
1165"DATA",1130580001.101,56,6,2,0)
1166diagnosis of diabetic retinopathy who had a dilated macular or fundus
1167"DATA",1130580001.101,56,6,3,0)
1168exam performed which included documentation of the level of severity
1169"DATA",1130580001.101,56,6,4,0)
1170of retinopathy and the presence or absence of macular edema during
1171"DATA",1130580001.101,56,6,5,0)
1172one or more office visits within 12 months.
1173"DATA",1130580001.101,56,7)
1174NQF0088^^^^
1175"DATA",1130580001.101,57,0)
1176MU EP NQF 0089^^
1177"DATA",1130580001.101,57,1)
1178Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1179"DATA",1130580001.101,57,5)
1180Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1181"DATA",1130580001.101,57,6,0)
1182^^6^6^3110430^
1183"DATA",1130580001.101,57,6,1,0)
1184Percentage of patients aged 18 years and older with a
1185"DATA",1130580001.101,57,6,2,0)
1186diagnosis of diabetic retinopathy who had a dilated macular or fundus
1187"DATA",1130580001.101,57,6,3,0)
1188exam performed with documented communication to the physician who
1189"DATA",1130580001.101,57,6,4,0)
1190manages the ongoing care of the patient with diabetes mellitus
1191"DATA",1130580001.101,57,6,5,0)
1192regarding the findings of the macular or fundus exam at least once
1193"DATA",1130580001.101,57,6,6,0)
1194within 12 months.
1195"DATA",1130580001.101,57,7)
1196NQF0089^^^^
1197"DATA",1130580001.101,58,0)
1198MU EP NQF 0047^^
1199"DATA",1130580001.101,58,1)
1200Asthma Pharmacologic Therapy
1201"DATA",1130580001.101,58,5)
1202Asthma Pharmacologic Therapy
1203"DATA",1130580001.101,58,6,0)
1204^1130580001.111^4^4^3110430^^
1205"DATA",1130580001.101,58,6,1,0)
1206Percentage of patients aged 5 through 40 years with a
1207"DATA",1130580001.101,58,6,2,0)
1208diagnosis of mild, moderate, or severe persistent asthma who were
1209"DATA",1130580001.101,58,6,3,0)
1210prescribed either the preferred long-term control medication (inhaled
1211"DATA",1130580001.101,58,6,4,0)
1212corticosteroid) or an acceptable alternative treatment
1213"DATA",1130580001.101,58,7)
1214NQF0047^^^^
1215"DATA",1130580001.101,59,0)
1216MU EP NQF 0001^^
1217"DATA",1130580001.101,59,1)
1218Asthma Assessment
1219"DATA",1130580001.101,59,5)
1220Asthma Assessment
1221"DATA",1130580001.101,59,6,0)
1222^^5^5^3110430^
1223"DATA",1130580001.101,59,6,1,0)
1224Percentage of patients aged 5 through 40 years with a
1225"DATA",1130580001.101,59,6,2,0)
1226diagnosis of asthma and who have been seen for at least 2 office
1227"DATA",1130580001.101,59,6,3,0)
1228visits, who were evaluated during at least one office visit within 12
1229"DATA",1130580001.101,59,6,4,0)
1230months for the frequency (numeric) of daytime and nocturnal asthma
1231"DATA",1130580001.101,59,6,5,0)
1232symptoms.
1233"DATA",1130580001.101,59,7)
1234NQF0001^^^^
1235"DATA",1130580001.101,60,0)
1236MU EP NQF 0002^^
1237"DATA",1130580001.101,60,1)
1238Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
1239"DATA",1130580001.101,60,5)
1240Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
1241"DATA",1130580001.101,60,6,0)
1242^^4^4^3110430^
1243"DATA",1130580001.101,60,6,1,0)
1244Percentage of female patients aged 18 years and older
1245"DATA",1130580001.101,60,6,2,0)
1246with Stage IC through IIIC, ER or PR positive breast cancer who were
1247"DATA",1130580001.101,60,6,3,0)
1248prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
1249"DATA",1130580001.101,60,6,4,0)
1250reporting period.
1251"DATA",1130580001.101,60,7)
1252NQF0002^^^^
1253"DATA",1130580001.101,61,0)
1254MU EP NQF 0385^^
1255"DATA",1130580001.101,61,1)
1256Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1257"DATA",1130580001.101,61,5)
1258Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1259"DATA",1130580001.101,61,6,0)
1260^^4^4^3110430^
1261"DATA",1130580001.101,61,6,1,0)
1262Percentage of patients aged 18 years and older with
1263"DATA",1130580001.101,61,6,2,0)
1264Stage IIIA through IIIC colon cancer who are referred for adjuvant
1265"DATA",1130580001.101,61,6,3,0)
1266chemotherapy, prescribed adjuvant chemotherapy, or have previously
1267"DATA",1130580001.101,61,6,4,0)
1268received adjuvant chemotherapy within the 12-month reporting period
1269"DATA",1130580001.101,61,7)
1270NQF0385^^^^
1271"DATA",1130580001.101,62,0)
1272MU EP NQF 0389^^
1273"DATA",1130580001.101,62,1)
1274Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1275"DATA",1130580001.101,62,5)
1276Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1277"DATA",1130580001.101,62,6,0)
1278^^5^5^3110430^
1279"DATA",1130580001.101,62,6,1,0)
1280Percentage of patients, regardless of age, with a diagnosis of
1281"DATA",1130580001.101,62,6,2,0)
1282prostate cancer at low risk of recurrence receiving interstitial prostate
1283"DATA",1130580001.101,62,6,3,0)
1284brachytherapy, OR external beam radiotherapy to the prostate, OR radical
1285"DATA",1130580001.101,62,6,4,0)
1286prostatectomy, OR cryotherapy who did not have a bone scan performed at
1287"DATA",1130580001.101,62,6,5,0)
1288any time since diagnosis of prostate cancer.
1289"DATA",1130580001.101,62,7)
1290NQF0389^^^^
1291"DATA",1130580001.101,63,0)
1292MU EP NQF 0027^^
1293"DATA",1130580001.101,63,1)
1294Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
1295"DATA",1130580001.101,63,5)
1296Smoking and Tobacco Use Cessation
1297"DATA",1130580001.101,63,6,0)
1298^^5^5^3110430^
1299"DATA",1130580001.101,63,6,1,0)
1300Percentage of patients 18 years of age and older who were
1301"DATA",1130580001.101,63,6,2,0)
1302current smokers or tobacco users, who were seen by a practitioner during
1303"DATA",1130580001.101,63,6,3,0)
1304the measurement year and who received advice to quit smoking or tobacco
1305"DATA",1130580001.101,63,6,4,0)
1306use or whose practitioner recommended or discussed smoking or tobacco use
1307"DATA",1130580001.101,63,6,5,0)
1308cessation medications, methods or strategies
1309"DATA",1130580001.101,63,7)
1310NQF0027^^^^
1311"DATA",1130580001.101,64,0)
1312MU EP NQF 0055^^
1313"DATA",1130580001.101,64,1)
1314Diabetes: Eye Exam
1315"DATA",1130580001.101,64,5)
1316Diabetes: Eye Exam
1317"DATA",1130580001.101,64,6,0)
1318^^3^3^3110430^
1319"DATA",1130580001.101,64,6,1,0)
1320Percentage of patients 18 -75 years of age with diabetes (type 1
1321"DATA",1130580001.101,64,6,2,0)
1322or type 2) who had a retinal or dilated eye exam or a negative retinal
1323"DATA",1130580001.101,64,6,3,0)
1324exam (no evidence of retinopathy) by an eye care professional
1325"DATA",1130580001.101,64,7)
1326NQF0055^^^^
1327"DATA",1130580001.101,65,0)
1328MU EP NQF 0062^^
1329"DATA",1130580001.101,65,1)
1330Diabetes: Urine Screening
1331"DATA",1130580001.101,65,5)
1332Diabetes: Urine Screening
1333"DATA",1130580001.101,65,6,0)
1334^^3^3^3110430^
1335"DATA",1130580001.101,65,6,1,0)
1336Percentage of patients 18 - 75 years of age with diabetes (type 1
1337"DATA",1130580001.101,65,6,2,0)
1338or type 2) who had a nephropathy screening test or evidence of
1339"DATA",1130580001.101,65,6,3,0)
1340nephropathy.
1341"DATA",1130580001.101,65,7)
1342NQF0062^^^^
1343"DATA",1130580001.101,66,0)
1344MU EP NQF 0056^^
1345"DATA",1130580001.101,66,1)
1346Diabetes: Foot Exam
1347"DATA",1130580001.101,66,5)
1348Diabetes: Foot Exam
1349"DATA",1130580001.101,66,6,0)
1350^^3^3^3110430^
1351"DATA",1130580001.101,66,6,1,0)
1352The percentage of patients aged 18 - 75 years with diabetes
1353"DATA",1130580001.101,66,6,2,0)
1354(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1355"DATA",1130580001.101,66,6,3,0)
1356with monofilament, or pulse exam).
1357"DATA",1130580001.101,66,7)
1358NQF0056^^^^
1359"DATA",1130580001.101,67,0)
1360MU EP NQF 0074^^
1361"DATA",1130580001.101,67,1)
1362Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1363"DATA",1130580001.101,67,5)
1364Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1365"DATA",1130580001.101,67,6,0)
1366^^3^3^3110430^
1367"DATA",1130580001.101,67,6,1,0)
1368Percentage of patients aged 18 years and older with a
1369"DATA",1130580001.101,67,6,2,0)
1370diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1371"DATA",1130580001.101,67,6,3,0)
1372on current ACC/AHA guidelines).
1373"DATA",1130580001.101,67,7)
1374NQF0074^^^^
1375"DATA",1130580001.101,68,0)
1376MU EP NQF 0084^^
1377"DATA",1130580001.101,68,1)
1378Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1379"DATA",1130580001.101,68,5)
1380Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1381"DATA",1130580001.101,68,6,0)
1382^^3^3^3110430^
1383"DATA",1130580001.101,68,6,1,0)
1384Percentage of all patients aged 18 years and older with a
1385"DATA",1130580001.101,68,6,2,0)
1386diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1387"DATA",1130580001.101,68,6,3,0)
1388who were prescribed warfarin therapy.
1389"DATA",1130580001.101,68,7)
1390NQF0084^^^^
1391"DATA",1130580001.101,69,0)
1392MU EP NQF 0073^^
1393"DATA",1130580001.101,69,1)
1394Ischemic Vascular Disease (IVD): Blood Pressure Management
1395"DATA",1130580001.101,69,5)
1396Ischemic Vascular Disease (IVD): Blood Pressure Management
1397"DATA",1130580001.101,69,6,0)
1398^^11^11^3110430^
1399"DATA",1130580001.101,69,6,1,0)
1400Percentage of patients 18 years of age and older who
1401"DATA",1130580001.101,69,6,2,0)
1402were discharged alive for acute myocardial infarction (AMI), coronary
1403"DATA",1130580001.101,69,6,3,0)
1404artery bypass graft (CABG) or percutaneous transluminal coronary
1405"DATA",1130580001.101,69,6,4,0)
1406Percentage of patients 18 years of age and older who
1407"DATA",1130580001.101,69,6,5,0)
1408were discharged alive for acute myocardial infarction (AMI), coronary
1409"DATA",1130580001.101,69,6,6,0)
1410artery bypass graft (CABG) or percutaneous transluminal coronary
1411"DATA",1130580001.101,69,6,7,0)
1412angioplasty (PTCA) from January 1- November 1 of the year prior to
1413"DATA",1130580001.101,69,6,8,0)
1414the measurement year, or who had a diagnosis of ischemic vascular
1415"DATA",1130580001.101,69,6,9,0)
1416disease (IVD) during the measurement year and the year prior to the
1417"DATA",1130580001.101,69,6,10,0)
1418measurement year and whose recent blood pressure is in control
1419"DATA",1130580001.101,69,6,11,0)
1420(<140/90 mmHg).
1421"DATA",1130580001.101,69,7)
1422NQF0073^^^^
1423"DATA",1130580001.101,70,0)
1424MU EP NQF 0068^^
1425"DATA",1130580001.101,70,1)
1426Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1427"DATA",1130580001.101,70,5)
1428 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1429"DATA",1130580001.101,70,6,0)
1430^^8^8^3110430^
1431"DATA",1130580001.101,70,6,1,0)
1432 Percentage of patients 18 years of age and older who were
1433"DATA",1130580001.101,70,6,2,0)
1434discharged alive for acute myocardial infarction (AMI), coronary artery
1435"DATA",1130580001.101,70,6,3,0)
1436bypass graft (CABG) or percutaneous transluminal coronary
1437"DATA",1130580001.101,70,6,4,0)
1438angioplasty (PTCA) from January 1-November 1 of the year prior to the
1439"DATA",1130580001.101,70,6,5,0)
1440measurement year, or who had a diagnosis of ischemic vascular
1441"DATA",1130580001.101,70,6,6,0)
1442disease (IVD) during the measurement year and the year prior to the
1443"DATA",1130580001.101,70,6,7,0)
1444measurement year and who had documentation of use of aspirin or
1445"DATA",1130580001.101,70,6,8,0)
1446another antithrombotic during the measurement year
1447"DATA",1130580001.101,70,7)
1448NQF0068^^^^
1449"DATA",1130580001.101,71,0)
1450MU EP NQF 0004^^
1451"DATA",1130580001.101,71,1)
1452 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1453"DATA",1130580001.101,71,5)
1454Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1455"DATA",1130580001.101,71,6,0)
1456^^6^6^3110430^
1457"DATA",1130580001.101,71,6,1,0)
1458The percentage of adolescent and adult patients with a new
1459"DATA",1130580001.101,71,6,2,0)
1460episode of alcohol and other drug (AOD) dependence who initiate treatment
1461"DATA",1130580001.101,71,6,3,0)
1462through an inpatient AOD admission, outpatient visit, intensive
1463"DATA",1130580001.101,71,6,4,0)
1464outpatient encounter or partial hospitalization within 14 days of the
1465"DATA",1130580001.101,71,6,5,0)
1466diagnosis and who initiated treatment and who had two or more additional
1467"DATA",1130580001.101,71,6,6,0)
1468services with an AOD diagnosis within 30 days of the initiation visit.
1469"DATA",1130580001.101,71,7)
1470NQF0004^^^^
1471"DATA",1130580001.101,72,0)
1472MU EP NQF 0012^^
1473"DATA",1130580001.101,72,1)
1474Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1475"DATA",1130580001.101,72,5)
1476Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1477"DATA",1130580001.101,72,6,0)
1478^^3^3^3110430^
1479"DATA",1130580001.101,72,6,1,0)
1480Percentage of patients, regardless of age, who gave birth during
1481"DATA",1130580001.101,72,6,2,0)
1482a 12-month period who were screened for HIV infection during the first or
1483"DATA",1130580001.101,72,6,3,0)
1484second prenatal care visit.
1485"DATA",1130580001.101,72,7)
1486NQF0012^^^^
1487"DATA",1130580001.101,73,0)
1488MU EP NQF 0014^^
1489"DATA",1130580001.101,73,1)
1490Prenatal Care: Anti-D Immune Globulin
1491"DATA",1130580001.101,73,5)
1492Prenatal Care: Anti-D Immune Globulin
1493"DATA",1130580001.101,73,6,0)
1494^^3^3^3110430^
1495"DATA",1130580001.101,73,6,1,0)
1496Percentage of D (Rh) negative, unsensitized patients, regardless
1497"DATA",1130580001.101,73,6,2,0)
1498of age, who gave birth during a 12-month period who received anti-D
1499"DATA",1130580001.101,73,6,3,0)
1500immune globulin at 26-30 weeks gestation.
1501"DATA",1130580001.101,73,7)
1502NQD0014^^^^
1503"DATA",1130580001.101,74,0)
1504MU EP NQF 0018^^
1505"DATA",1130580001.101,74,1)
1506Controlling High Blood Pressure
1507"DATA",1130580001.101,74,5)
1508Controlling High Blood Pressure
1509"DATA",1130580001.101,74,6,0)
1510^^3^3^3110430^
1511"DATA",1130580001.101,74,6,1,0)
1512The percentage of patients 18-85 years of age who had a
1513"DATA",1130580001.101,74,6,2,0)
1514diagnosis of hypertension and whose BP was adequately controlled during
1515"DATA",1130580001.101,74,6,3,0)
1516the measurement year
1517"DATA",1130580001.101,74,7)
1518NQF0018^^^^
1519"DATA",1130580001.101,75,0)
1520MU EP NQF 0032^^
1521"DATA",1130580001.101,75,1)
1522Cervical Cancer Screening
1523"DATA",1130580001.101,75,5)
1524Cervical Cancer Screening
1525"DATA",1130580001.101,75,6,0)
1526^^2^2^3110430^
1527"DATA",1130580001.101,75,6,1,0)
1528Percentage of women 21-64 years of age, who received one or
1529"DATA",1130580001.101,75,6,2,0)
1530more Pap tests to screen for cervical cancer
1531"DATA",1130580001.101,75,7)
1532NQF0032^^^^
1533"DATA",1130580001.101,76,0)
1534MU EP NQF 0033^^
1535"DATA",1130580001.101,76,1)
1536Chlamydia Screening for Women
1537"DATA",1130580001.101,76,5)
1538Chlamydia Screening for Women
1539"DATA",1130580001.101,76,6,0)
1540^^3^3^3110430^
1541"DATA",1130580001.101,76,6,1,0)
1542Percentage of women 15- 24 years of age who were identified as sexually
1543"DATA",1130580001.101,76,6,2,0)
1544active and who had at least one test for chlamydia during the measurement
1545"DATA",1130580001.101,76,6,3,0)
1546year.
1547"DATA",1130580001.101,76,7)
1548NQF0033^^^^
1549"DATA",1130580001.101,77,0)
1550MU EP NQF 0036^^
1551"DATA",1130580001.101,77,1)
1552Use of Appropriate Medications for Asthma
1553"DATA",1130580001.101,77,5)
1554Use of Appropriate Medications for Asthma
1555"DATA",1130580001.101,77,6,0)
1556^^4^4^3110430^
1557"DATA",1130580001.101,77,6,1,0)
1558Percentage of patients 5 - 50 years of age who were identified as having
1559"DATA",1130580001.101,77,6,2,0)
1560persistent asthma and were appropriately prescribed medication during the
1561"DATA",1130580001.101,77,6,3,0)
1562measurement year. Report three age stratifications (5-11 years, 12-50
1563"DATA",1130580001.101,77,6,4,0)
1564years, and total).
1565"DATA",1130580001.101,77,7)
1566NQF0036^^^^
1567"DATA",1130580001.101,78,0)
1568MU EP NQF 0052^^
1569"DATA",1130580001.101,78,1)
1570Low Back Pain: Use of Imaging Studies
1571"DATA",1130580001.101,78,5)
1572Low Back Pain: Use of Imaging Studies
1573"DATA",1130580001.101,78,6,0)
1574^1130580001.111^3^3^3110430^^
1575"DATA",1130580001.101,78,6,1,0)
1576Percentage of patients with a primary diagnosis of low back pain
1577"DATA",1130580001.101,78,6,2,0)
1578who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1579"DATA",1130580001.101,78,6,3,0)
1580days of diagnosis.
1581"DATA",1130580001.101,78,7)
1582NQF0052^^^^
1583"DATA",1130580001.101,79,0)
1584MU EP NQF 0075^^
1585"DATA",1130580001.101,79,1)
1586Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1587"DATA",1130580001.101,79,5)
1588Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1589"DATA",1130580001.101,79,6,0)
1590^^7^7^3110430^
1591"DATA",1130580001.101,79,6,1,0)
1592Percentage of patients 18 years of age and older who were discharged alive
1593"DATA",1130580001.101,79,6,2,0)
1594for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1595"DATA",1130580001.101,79,6,3,0)
1596or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1597"DATA",1130580001.101,79,6,4,0)
1598of the year prior to the measurement year, or who had a diagnosis of
1599"DATA",1130580001.101,79,6,5,0)
1600ischemic vascular disease (IVD) during the measurement year and the year
1601"DATA",1130580001.101,79,6,6,0)
1602prior to the measurement year and who had a complete lipid profile
1603"DATA",1130580001.101,79,6,7,0)
1604performed during the measurement year and whose LDL-C<100 mg/dL
1605"DATA",1130580001.101,79,7)
1606NQF0075^^^^
1607"DATA",1130580001.101,80,0)
1608MU EP NQF 0575^^
1609"DATA",1130580001.101,80,1)
1610Diabetes: Hemoglobin A1c Control (<8.0%)
1611"DATA",1130580001.101,80,5)
1612Diabetes: Hemoglobin A1c Control (<8.0%)
1613"DATA",1130580001.101,80,6,0)
1614^^2^2^3110430^
1615"DATA",1130580001.101,80,6,1,0)
1616The percentage of patients 18-75 years of age with diabetes
1617"DATA",1130580001.101,80,6,2,0)
1618(type 1 or type 2) who had hemoglobin A1c <8.0%
1619"DATA",1130580001.101,80,7)
1620NQF0575^^^^
1621"DATA",1130580001.101,81,0)
1622MU EP NQF 0028B^^
1623"DATA",1130580001.101,81,1)
1624NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1625"DATA",1130580001.101,81,5)
1626NQF0028B Tobacco Use Assessment and Cessation Intervention
1627"DATA",1130580001.101,81,6,0)
1628^1130580001.111^7^7^3110625^^^^
1629"DATA",1130580001.101,81,6,1,0)
1630 Percentage of patients aged 18 years and
1631"DATA",1130580001.101,81,6,2,0)
1632older who have been seen for at least 2 office visits who
1633"DATA",1130580001.101,81,6,3,0)
1634were queried about tobacco use one or more times within
1635"DATA",1130580001.101,81,6,4,0)
163624 months b. Percentage of patients aged 18 years and
1637"DATA",1130580001.101,81,6,5,0)
1638older identified as tobacco users within the past 24
1639"DATA",1130580001.101,81,6,6,0)
1640months and have been seen for at least 2 office visits,
1641"DATA",1130580001.101,81,6,7,0)
1642who received cessation intervention.
1643"DATA",1130580001.101,81,7)
1644NQF0028B^^^^^^154^160
1645"DATA",1130580001.101,82,0)
1646MU EP NQF 0024 2-10Y
1647"DATA",1130580001.101,82,1)
1648NQF0024 Weight Assessment and Counseling for Children and Adolescents (2-10)
1649"DATA",1130580001.101,82,5)
1650Weight Assessment and Counseling for Children 2-10 Years Old
1651"DATA",1130580001.101,82,6,0)
1652^^6^6^3120803^
1653"DATA",1130580001.101,82,6,1,0)
1654Percentage of patients 2-10 years of age
1655"DATA",1130580001.101,82,6,2,0)
1656who had an outpatient visit with a Primary Care Physician
1657"DATA",1130580001.101,82,6,3,0)
1658(PCP) or OB/GYN and who had evidence of BMI
1659"DATA",1130580001.101,82,6,4,0)
1660percentile documentation, counseling for nutrition and
1661"DATA",1130580001.101,82,6,5,0)
1662counseling for physical activity during the measurement
1663"DATA",1130580001.101,82,6,6,0)
1664year. Only for those 2-10 years of age.
1665"DATA",1130580001.101,82,7)
1666NQF0024 2-10Y^^^^^^334^338
1667"DATA",1130580001.101,83,0)
1668MU EP NQF 0038 NUM1 DPT^^
1669"DATA",1130580001.101,83,5)
1670NQF0038 NUM1 DPT
1671"DATA",1130580001.101,83,7)
1672NQF0038 NUM1 DPT^^^^^^329^192^11
1673"DATA",1130580001.101,84,0)
1674MU EP NQF 0038 NUM2 IPV^^
1675"DATA",1130580001.101,84,5)
1676NQF0038 NUM2 IPV
1677"DATA",1130580001.101,84,7)
1678NQF0038 NUM2 IPV^^^^^^224^192^11
1679"DATA",1130580001.101,85,0)
1680MU EP NQF 0038 NUM3 MMR^^
1681"DATA",1130580001.101,85,5)
1682NQF0038 NUM3 MMR
1683"DATA",1130580001.101,85,7)
1684NQF0038 NUM3 MMR^^^^^^183^192^11
1685"DATA",1130580001.101,86,0)
1686MU EP NQF 0038 NUM4 HiB^^
1687"DATA",1130580001.101,86,5)
1688NQF0038 NUM4 HiB
1689"DATA",1130580001.101,86,7)
1690NQF0038 NUM4 HiB^^^^^^189^192^11
1691"DATA",1130580001.101,87,0)
1692MU EP NQF 0038 NUM5 HEP B^^
1693"DATA",1130580001.101,87,5)
1694NQF0038 NUM5 HEP B
1695"DATA",1130580001.101,87,7)
1696NQF0038 NUM5 HEP B^^^^^^194^192^11
1697"DATA",1130580001.101,88,0)
1698MU EP NQF 0038 NUM6 VZV^^
1699"DATA",1130580001.101,88,5)
1700NQF0038 NUM6 VZV
1701"DATA",1130580001.101,88,7)
1702NQF0038 NUM6 VZV^^^^^^198^192^11
1703"DATA",1130580001.101,89,0)
1704MU EP NQF 0038 NUM7 PCV^^
1705"DATA",1130580001.101,89,5)
1706NQF0038 NUM7 PCV
1707"DATA",1130580001.101,89,7)
1708NQF0038 NUM7 PCV^^^^^^205^192^11
1709"DATA",1130580001.101,90,0)
1710MU EP NQF 0038 NUM8 HEP A^^
1711"DATA",1130580001.101,90,5)
1712NQF0038 NUM8 HEP A
1713"DATA",1130580001.101,90,7)
1714NQF0038 NUM8 HEP A^^^^^^208^192^11
1715"DATA",1130580001.101,91,0)
1716MU EP NQF 0038 NUM9 RV^^
1717"DATA",1130580001.101,91,5)
1718NQF0038 NUM9
1719"DATA",1130580001.101,91,7)
1720NQF0038 NUM9^^^^^^216^192^11
1721"DATA",1130580001.101,92,0)
1722MU EP NQF 0038 NUM10 FLU^^
1723"DATA",1130580001.101,92,5)
1724NQF0038 NUM10
1725"DATA",1130580001.101,92,7)
1726NQF0038 NUM10^^^^^^331^192^11
1727"DATA",1130580001.101,93,0)
1728MU EP NQF 0038 NUM11 COMBO5^^
1729"DATA",1130580001.101,93,5)
1730NQF0038 NUM11 COMBO5
1731"DATA",1130580001.101,93,7)
1732NQF0038 NUM11 COMBO5^^^^^^228^192^11
1733"DATA",1130580001.101,94,0)
1734MU EP NQF 0038 NUM12 COMBO6^^
1735"DATA",1130580001.101,94,5)
1736NQF0038 NUM12 COMBO6
1737"DATA",1130580001.101,94,7)
1738NQF0038 NUM12 COMBO6^^^^^^231^192^11
1739"DATA",1130580001.101,95,0)
1740MU 2011 INP ADV DIRECTIVES^^
1741"DATA",1130580001.101,95,5)
1742Advance Directives
1743"DATA",1130580001.101,95,7)
1744^^^^
1745"DATA",1130580001.101,96,0)
1746MU 2011 INP CPOE^^
1747"DATA",1130580001.101,96,5)
1748CPOE for Medications
1749"DATA",1130580001.101,96,7)
1750^^^^
1751"DATA",1130580001.101,97,0)
1752MU 2011 INP MED RECON^^
1753"DATA",1130580001.101,97,5)
1754Medication Reconcilliation
1755"DATA",1130580001.101,97,7)
1756^^^^
1757"DATA",1130580001.101,98,0)
1758MU 2011 INP PROBLEM LIST^^
1759"DATA",1130580001.101,98,5)
1760Problem List
1761"DATA",1130580001.101,98,7)
1762^^^^
1763"DATA",1130580001.101,99,0)
1764MU 2011 INP VITAL SIGNS^^
1765"DATA",1130580001.101,99,5)
1766Record Vital Signs
1767"DATA",1130580001.101,99,7)
1768^^^^
1769"DATA",1130580001.101,100,0)
1770MU 2011 INP SMOKING STATUS^^
1771"DATA",1130580001.101,100,5)
1772Smoking Status
1773"DATA",1130580001.101,100,7)
1774^^^^
1775"DATA",1130580001.101,101,0)
1776MU 2011 INP MED LIST^^
1777"DATA",1130580001.101,101,5)
1778Active Medication List
1779"DATA",1130580001.101,101,7)
1780^^^^
1781"DATA",1130580001.101,102,0)
1782MU 2011 INP ALLERGY LIST^^
1783"DATA",1130580001.101,102,5)
1784Medication Allergy List
1785"DATA",1130580001.101,102,7)
1786^^^^
1787"DATA",1130580001.101,103,0)
1788MU 2011 INP DEMOGRAPHICS^^
1789"DATA",1130580001.101,103,5)
1790Record Demographics
1791"DATA",1130580001.101,103,7)
1792^^^^
1793"DATA",1130580001.101,104,0)
1794MU EP NQF 0024 11-17Y
1795"DATA",1130580001.101,104,1)
1796NQF0024 Weight Assessment and Counseling for Children and Adolescents (11-17)
1797"DATA",1130580001.101,104,5)
1798Weight Assessment and Counseling for Children and Adolescents 11-17 years old
1799"DATA",1130580001.101,104,6,0)
1800^^6^6^3120803^
1801"DATA",1130580001.101,104,6,1,0)
1802Percentage of patients 11-17 years of age
1803"DATA",1130580001.101,104,6,2,0)
1804who had an outpatient visit with a Primary Care Physician
1805"DATA",1130580001.101,104,6,3,0)
1806(PCP) or OB/GYN and who had evidence of BMI
1807"DATA",1130580001.101,104,6,4,0)
1808percentile documentation, counseling for nutrition and
1809"DATA",1130580001.101,104,6,5,0)
1810counseling for physical activity during the measurement
1811"DATA",1130580001.101,104,6,6,0)
1812year. Only for those 11-17 years old.
1813"DATA",1130580001.101,104,7)
1814NQF0024 11-17Y^^^^^^336^340
1815"FIA",1130580001.101)
1816C0Q QUALITY MEASURE
1817"FIA",1130580001.101,0)
1818^C0Q(101,
1819"FIA",1130580001.101,0,0)
18201130580001.101I
1821"FIA",1130580001.101,0,1)
1822y^y^f^^y^^y^o^n
1823"FIA",1130580001.101,0,10)
1824
1825"FIA",1130580001.101,0,11)
1826
1827"FIA",1130580001.101,0,"RLRO")
1828
1829"FIA",1130580001.101,0,"VR")
18301.0^C0Q
1831"FIA",1130580001.101,1130580001.101)
18320
1833"FIA",1130580001.101,1130580001.111)
18340
1835"FRV1",1130580001.101,"104,7",7)
1836MU NQF0024 BMI PERCENTILE 11-17Y RS
1837"FRV1",1130580001.101,"104,7",7,"F")
1838;PXRM(810.4,
1839"FRV1",1130580001.101,"104,7",8)
1840MU NQF0024 BMI 11-17Y DENOM RS
1841"FRV1",1130580001.101,"104,7",8,"F")
1842;PXRM(810.4,
1843"FRV1",1130580001.101,"23,7",7)
1844MU ED-1 NUMER RS
1845"FRV1",1130580001.101,"23,7",7,"F")
1846;PXRM(810.4,
1847"FRV1",1130580001.101,"23,7",8)
1848MU ED-1 DENOM RS
1849"FRV1",1130580001.101,"23,7",8,"F")
1850;PXRM(810.4,
1851"FRV1",1130580001.101,"24,7",7)
1852MU ED-2 NUMER RS
1853"FRV1",1130580001.101,"24,7",7,"F")
1854;PXRM(810.4,
1855"FRV1",1130580001.101,"24,7",8)
1856MU ED-2 DENOM RS
1857"FRV1",1130580001.101,"24,7",8,"F")
1858;PXRM(810.4,
1859"FRV1",1130580001.101,"25,7",7)
1860MU STK-2 NUMER RS
1861"FRV1",1130580001.101,"25,7",7,"F")
1862;PXRM(810.4,
1863"FRV1",1130580001.101,"25,7",8)
1864MU STK-2 DENOM RS
1865"FRV1",1130580001.101,"25,7",8,"F")
1866;PXRM(810.4,
1867"FRV1",1130580001.101,"26,7",7)
1868MU STK-3 NUMER RS
1869"FRV1",1130580001.101,"26,7",7,"F")
1870;PXRM(810.4,
1871"FRV1",1130580001.101,"26,7",8)
1872MU STK-3 DENOM RS
1873"FRV1",1130580001.101,"26,7",8,"F")
1874;PXRM(810.4,
1875"FRV1",1130580001.101,"27,7",7)
1876MU STK-4 NUMER RS
1877"FRV1",1130580001.101,"27,7",7,"F")
1878;PXRM(810.4,
1879"FRV1",1130580001.101,"27,7",8)
1880MU STK-4 DENOM RS
1881"FRV1",1130580001.101,"27,7",8,"F")
1882;PXRM(810.4,
1883"FRV1",1130580001.101,"28,7",7)
1884MU STK-5 NUMER RS
1885"FRV1",1130580001.101,"28,7",7,"F")
1886;PXRM(810.4,
1887"FRV1",1130580001.101,"28,7",8)
1888MU STK-5 DENOM RS
1889"FRV1",1130580001.101,"28,7",8,"F")
1890;PXRM(810.4,
1891"FRV1",1130580001.101,"29,7",7)
1892MU STK-6 NUMER RS
1893"FRV1",1130580001.101,"29,7",7,"F")
1894;PXRM(810.4,
1895"FRV1",1130580001.101,"29,7",8)
1896MU STK-6 DENOM RS
1897"FRV1",1130580001.101,"29,7",8,"F")
1898;PXRM(810.4,
1899"FRV1",1130580001.101,"30,7",7)
1900MU STK-8 NUMER RS
1901"FRV1",1130580001.101,"30,7",7,"F")
1902;PXRM(810.4,
1903"FRV1",1130580001.101,"30,7",8)
1904MU STK-8 DENOM RS
1905"FRV1",1130580001.101,"30,7",8,"F")
1906;PXRM(810.4,
1907"FRV1",1130580001.101,"31,7",7)
1908MU STK-10 NUMER RS
1909"FRV1",1130580001.101,"31,7",7,"F")
1910;PXRM(810.4,
1911"FRV1",1130580001.101,"31,7",8)
1912MU STK-10 DENOM RS
1913"FRV1",1130580001.101,"31,7",8,"F")
1914;PXRM(810.4,
1915"FRV1",1130580001.101,"32,7",7)
1916MU VTE-1 NUMER RS
1917"FRV1",1130580001.101,"32,7",7,"F")
1918;PXRM(810.4,
1919"FRV1",1130580001.101,"32,7",8)
1920MU VTE-1 DENOM RS
1921"FRV1",1130580001.101,"32,7",8,"F")
1922;PXRM(810.4,
1923"FRV1",1130580001.101,"33,7",7)
1924MU VTE-2 NUMER RS
1925"FRV1",1130580001.101,"33,7",7,"F")
1926;PXRM(810.4,
1927"FRV1",1130580001.101,"33,7",8)
1928MU VTE-2 DENOM RS
1929"FRV1",1130580001.101,"33,7",8,"F")
1930;PXRM(810.4,
1931"FRV1",1130580001.101,"34,7",7)
1932MU VTE-3 NUMER RS
1933"FRV1",1130580001.101,"34,7",7,"F")
1934;PXRM(810.4,
1935"FRV1",1130580001.101,"34,7",8)
1936MU VTE-3 DENOM RS
1937"FRV1",1130580001.101,"34,7",8,"F")
1938;PXRM(810.4,
1939"FRV1",1130580001.101,"35,7",7)
1940MU VTE-4 NUMER RS
1941"FRV1",1130580001.101,"35,7",7,"F")
1942;PXRM(810.4,
1943"FRV1",1130580001.101,"35,7",8)
1944MU VTE-4 DENOM RS
1945"FRV1",1130580001.101,"35,7",8,"F")
1946;PXRM(810.4,
1947"FRV1",1130580001.101,"36,7",7)
1948MU VTE-5 NUMER RS
1949"FRV1",1130580001.101,"36,7",7,"F")
1950;PXRM(810.4,
1951"FRV1",1130580001.101,"36,7",8)
1952MU VTE-5 DENOM RS
1953"FRV1",1130580001.101,"36,7",8,"F")
1954;PXRM(810.4,
1955"FRV1",1130580001.101,"37,7",7)
1956MU VTE-6 NUMER RS
1957"FRV1",1130580001.101,"37,7",7,"F")
1958;PXRM(810.4,
1959"FRV1",1130580001.101,"37,7",8)
1960MU VTE-6 DENOM RS
1961"FRV1",1130580001.101,"37,7",8,"F")
1962;PXRM(810.4,
1963"FRV1",1130580001.101,"39,7",7)
1964MU NQF0421 BMI NUM ALL RS
1965"FRV1",1130580001.101,"39,7",7,"F")
1966;PXRM(810.4,
1967"FRV1",1130580001.101,"39,7",8)
1968MU NQF0421 BMI DENOM ALL RS
1969"FRV1",1130580001.101,"39,7",8,"F")
1970;PXRM(810.4,
1971"FRV1",1130580001.101,"39,7",9)
1972MU NQF0421 ADULT BMI
1973"FRV1",1130580001.101,"39,7",9,"F")
1974;PXRM(810.2,
1975"FRV1",1130580001.101,"40,7",7)
1976MU NQF0013 HTN NUMER2 RS
1977"FRV1",1130580001.101,"40,7",7,"F")
1978;PXRM(810.4,
1979"FRV1",1130580001.101,"40,7",8)
1980MU NQF0013 HTN DENOM2 RS
1981"FRV1",1130580001.101,"40,7",8,"F")
1982;PXRM(810.4,
1983"FRV1",1130580001.101,"41,7",7)
1984MU NQF0028A TOBACCO SCREEN NUM RS
1985"FRV1",1130580001.101,"41,7",7,"F")
1986;PXRM(810.4,
1987"FRV1",1130580001.101,"41,7",8)
1988MU NQF0028B TOBACCO INTERV DENOM RS
1989"FRV1",1130580001.101,"41,7",8,"F")
1990;PXRM(810.4,
1991"FRV1",1130580001.101,"42,7",7)
1992MU NQF0041 FLU RS
1993"FRV1",1130580001.101,"42,7",7,"F")
1994;PXRM(810.4,
1995"FRV1",1130580001.101,"42,7",8)
1996MU NQF0041 FLU DENOM RS
1997"FRV1",1130580001.101,"42,7",8,"F")
1998;PXRM(810.4,
1999"FRV1",1130580001.101,"43,7",7)
2000MU NQF0024 BMI 2-17YR NUM RS
2001"FRV1",1130580001.101,"43,7",7,"F")
2002;PXRM(810.4,
2003"FRV1",1130580001.101,"43,7",8)
2004MU NQF0024 BMI 2-17YRS DEM RS
2005"FRV1",1130580001.101,"43,7",8,"F")
2006;PXRM(810.4,
2007"FRV1",1130580001.101,"45,7",7)
2008MU NQF0059 HBA1C NUM RS
2009"FRV1",1130580001.101,"45,7",7,"F")
2010;PXRM(810.4,
2011"FRV1",1130580001.101,"45,7",8)
2012MU NQF0059 DM DENOM-ALL RS
2013"FRV1",1130580001.101,"45,7",8,"F")
2014;PXRM(810.4,
2015"FRV1",1130580001.101,"46,7",7)
2016MU NQF0064 NUM LDL RS
2017"FRV1",1130580001.101,"46,7",7,"F")
2018;PXRM(810.4,
2019"FRV1",1130580001.101,"46,7",8)
2020MU NQF0059 DM DENOM-ALL RS
2021"FRV1",1130580001.101,"46,7",8,"F")
2022;PXRM(810.4,
2023"FRV1",1130580001.101,"47,7",7)
2024MU NQF0061 NUM DM BP<140/90 RS
2025"FRV1",1130580001.101,"47,7",7,"F")
2026;PXRM(810.4,
2027"FRV1",1130580001.101,"47,7",8)
2028MU NQF0059 DM DENOM-ALL RS
2029"FRV1",1130580001.101,"47,7",8,"F")
2030;PXRM(810.4,
2031"FRV1",1130580001.101,"81,7",7)
2032MU NQF0028B TOBACCO INTERV NUM2 RS
2033"FRV1",1130580001.101,"81,7",7,"F")
2034;PXRM(810.4,
2035"FRV1",1130580001.101,"81,7",8)
2036MU NQF0028B TOBACCO INTERV DENOM RS
2037"FRV1",1130580001.101,"81,7",8,"F")
2038;PXRM(810.4,
2039"FRV1",1130580001.101,"82,7",7)
2040MU NQF0024 BMI PERCENTILE 2-10Y RS
2041"FRV1",1130580001.101,"82,7",7,"F")
2042;PXRM(810.4,
2043"FRV1",1130580001.101,"82,7",8)
2044MU NQF0024 BMI 2-10Y DENOM RS
2045"FRV1",1130580001.101,"82,7",8,"F")
2046;PXRM(810.4,
2047"FRV1",1130580001.101,"83,7",7)
2048MU NQF0038 NUM1 DPT RS
2049"FRV1",1130580001.101,"83,7",7,"F")
2050;PXRM(810.4,
2051"FRV1",1130580001.101,"83,7",8)
2052MU NQF0038 DENOM RS
2053"FRV1",1130580001.101,"83,7",8,"F")
2054;PXRM(810.4,
2055"FRV1",1130580001.101,"83,7",9)
2056MU NQF0038 CHILDREN'S IMMUNIZATIONS
2057"FRV1",1130580001.101,"83,7",9,"F")
2058;PXRM(810.2,
2059"FRV1",1130580001.101,"84,7",7)
2060MU NQF0038 NUM2 IPV RS
2061"FRV1",1130580001.101,"84,7",7,"F")
2062;PXRM(810.4,
2063"FRV1",1130580001.101,"84,7",8)
2064MU NQF0038 DENOM RS
2065"FRV1",1130580001.101,"84,7",8,"F")
2066;PXRM(810.4,
2067"FRV1",1130580001.101,"84,7",9)
2068MU NQF0038 CHILDREN'S IMMUNIZATIONS
2069"FRV1",1130580001.101,"84,7",9,"F")
2070;PXRM(810.2,
2071"FRV1",1130580001.101,"85,7",7)
2072MU NQF0038 NUM3-ALL RS
2073"FRV1",1130580001.101,"85,7",7,"F")
2074;PXRM(810.4,
2075"FRV1",1130580001.101,"85,7",8)
2076MU NQF0038 DENOM RS
2077"FRV1",1130580001.101,"85,7",8,"F")
2078;PXRM(810.4,
2079"FRV1",1130580001.101,"85,7",9)
2080MU NQF0038 CHILDREN'S IMMUNIZATIONS
2081"FRV1",1130580001.101,"85,7",9,"F")
2082;PXRM(810.2,
2083"FRV1",1130580001.101,"86,7",7)
2084MU NQF0038 NUM4 HIB RS
2085"FRV1",1130580001.101,"86,7",7,"F")
2086;PXRM(810.4,
2087"FRV1",1130580001.101,"86,7",8)
2088MU NQF0038 DENOM RS
2089"FRV1",1130580001.101,"86,7",8,"F")
2090;PXRM(810.4,
2091"FRV1",1130580001.101,"86,7",9)
2092MU NQF0038 CHILDREN'S IMMUNIZATIONS
2093"FRV1",1130580001.101,"86,7",9,"F")
2094;PXRM(810.2,
2095"FRV1",1130580001.101,"87,7",7)
2096MU NQF0038 NUM5 RS
2097"FRV1",1130580001.101,"87,7",7,"F")
2098;PXRM(810.4,
2099"FRV1",1130580001.101,"87,7",8)
2100MU NQF0038 DENOM RS
2101"FRV1",1130580001.101,"87,7",8,"F")
2102;PXRM(810.4,
2103"FRV1",1130580001.101,"87,7",9)
2104MU NQF0038 CHILDREN'S IMMUNIZATIONS
2105"FRV1",1130580001.101,"87,7",9,"F")
2106;PXRM(810.2,
2107"FRV1",1130580001.101,"88,7",7)
2108MU NQF0038 NUM6 VZV RS
2109"FRV1",1130580001.101,"88,7",7,"F")
2110;PXRM(810.4,
2111"FRV1",1130580001.101,"88,7",8)
2112MU NQF0038 DENOM RS
2113"FRV1",1130580001.101,"88,7",8,"F")
2114;PXRM(810.4,
2115"FRV1",1130580001.101,"88,7",9)
2116MU NQF0038 CHILDREN'S IMMUNIZATIONS
2117"FRV1",1130580001.101,"88,7",9,"F")
2118;PXRM(810.2,
2119"FRV1",1130580001.101,"89,7",7)
2120MU NQF0038 NUM7 PCV RS
2121"FRV1",1130580001.101,"89,7",7,"F")
2122;PXRM(810.4,
2123"FRV1",1130580001.101,"89,7",8)
2124MU NQF0038 DENOM RS
2125"FRV1",1130580001.101,"89,7",8,"F")
2126;PXRM(810.4,
2127"FRV1",1130580001.101,"89,7",9)
2128MU NQF0038 CHILDREN'S IMMUNIZATIONS
2129"FRV1",1130580001.101,"89,7",9,"F")
2130;PXRM(810.2,
2131"FRV1",1130580001.101,"90,7",7)
2132MU NQF0038 NUM8 HEP A RS
2133"FRV1",1130580001.101,"90,7",7,"F")
2134;PXRM(810.4,
2135"FRV1",1130580001.101,"90,7",8)
2136MU NQF0038 DENOM RS
2137"FRV1",1130580001.101,"90,7",8,"F")
2138;PXRM(810.4,
2139"FRV1",1130580001.101,"90,7",9)
2140MU NQF0038 CHILDREN'S IMMUNIZATIONS
2141"FRV1",1130580001.101,"90,7",9,"F")
2142;PXRM(810.2,
2143"FRV1",1130580001.101,"91,7",7)
2144MU NQF0038 NUM9 RV RS
2145"FRV1",1130580001.101,"91,7",7,"F")
2146;PXRM(810.4,
2147"FRV1",1130580001.101,"91,7",8)
2148MU NQF0038 DENOM RS
2149"FRV1",1130580001.101,"91,7",8,"F")
2150;PXRM(810.4,
2151"FRV1",1130580001.101,"91,7",9)
2152MU NQF0038 CHILDREN'S IMMUNIZATIONS
2153"FRV1",1130580001.101,"91,7",9,"F")
2154;PXRM(810.2,
2155"FRV1",1130580001.101,"92,7",7)
2156MU NQF0038 NUM10 INFLUENZA RS
2157"FRV1",1130580001.101,"92,7",7,"F")
2158;PXRM(810.4,
2159"FRV1",1130580001.101,"92,7",8)
2160MU NQF0038 DENOM RS
2161"FRV1",1130580001.101,"92,7",8,"F")
2162;PXRM(810.4,
2163"FRV1",1130580001.101,"92,7",9)
2164MU NQF0038 CHILDREN'S IMMUNIZATIONS
2165"FRV1",1130580001.101,"92,7",9,"F")
2166;PXRM(810.2,
2167"FRV1",1130580001.101,"93,7",7)
2168MU NQF0038 NUM11 COMBO5 RS
2169"FRV1",1130580001.101,"93,7",7,"F")
2170;PXRM(810.4,
2171"FRV1",1130580001.101,"93,7",8)
2172MU NQF0038 DENOM RS
2173"FRV1",1130580001.101,"93,7",8,"F")
2174;PXRM(810.4,
2175"FRV1",1130580001.101,"93,7",9)
2176MU NQF0038 CHILDREN'S IMMUNIZATIONS
2177"FRV1",1130580001.101,"93,7",9,"F")
2178;PXRM(810.2,
2179"FRV1",1130580001.101,"94,7",7)
2180MU NQF0038 NUM12 COMBO6 RS
2181"FRV1",1130580001.101,"94,7",7,"F")
2182;PXRM(810.4,
2183"FRV1",1130580001.101,"94,7",8)
2184MU NQF0038 DENOM RS
2185"FRV1",1130580001.101,"94,7",8,"F")
2186;PXRM(810.4,
2187"FRV1",1130580001.101,"94,7",9)
2188MU NQF0038 CHILDREN'S IMMUNIZATIONS
2189"FRV1",1130580001.101,"94,7",9,"F")
2190;PXRM(810.2,
2191"FRV1K",1130580001.101,"104,7",7)
2192B
2193"FRV1K",1130580001.101,"104,7",7,1)
2194MU NQF0024 BMI PERCENTILE 11-17Y RS
2195"FRV1K",1130580001.101,"104,7",8)
2196B
2197"FRV1K",1130580001.101,"104,7",8,1)
2198MU NQF0024 BMI 11-17Y DENOM RS
2199"FRV1K",1130580001.101,"23,7",7)
2200B
2201"FRV1K",1130580001.101,"23,7",7,1)
2202MU ED-1 NUMER RS
2203"FRV1K",1130580001.101,"23,7",8)
2204B
2205"FRV1K",1130580001.101,"23,7",8,1)
2206MU ED-1 DENOM RS
2207"FRV1K",1130580001.101,"24,7",7)
2208B
2209"FRV1K",1130580001.101,"24,7",7,1)
2210MU ED-2 NUMER RS
2211"FRV1K",1130580001.101,"24,7",8)
2212B
2213"FRV1K",1130580001.101,"24,7",8,1)
2214MU ED-2 DENOM RS
2215"FRV1K",1130580001.101,"25,7",7)
2216B
2217"FRV1K",1130580001.101,"25,7",7,1)
2218MU STK-2 NUMER RS
2219"FRV1K",1130580001.101,"25,7",8)
2220B
2221"FRV1K",1130580001.101,"25,7",8,1)
2222MU STK-2 DENOM RS
2223"FRV1K",1130580001.101,"26,7",7)
2224B
2225"FRV1K",1130580001.101,"26,7",7,1)
2226MU STK-3 NUMER RS
2227"FRV1K",1130580001.101,"26,7",8)
2228B
2229"FRV1K",1130580001.101,"26,7",8,1)
2230MU STK-3 DENOM RS
2231"FRV1K",1130580001.101,"27,7",7)
2232B
2233"FRV1K",1130580001.101,"27,7",7,1)
2234MU STK-4 NUMER RS
2235"FRV1K",1130580001.101,"27,7",8)
2236B
2237"FRV1K",1130580001.101,"27,7",8,1)
2238MU STK-4 DENOM RS
2239"FRV1K",1130580001.101,"28,7",7)
2240B
2241"FRV1K",1130580001.101,"28,7",7,1)
2242MU STK-5 NUMER RS
2243"FRV1K",1130580001.101,"28,7",8)
2244B
2245"FRV1K",1130580001.101,"28,7",8,1)
2246MU STK-5 DENOM RS
2247"FRV1K",1130580001.101,"29,7",7)
2248B
2249"FRV1K",1130580001.101,"29,7",7,1)
2250MU STK-6 NUMER RS
2251"FRV1K",1130580001.101,"29,7",8)
2252B
2253"FRV1K",1130580001.101,"29,7",8,1)
2254MU STK-6 DENOM RS
2255"FRV1K",1130580001.101,"30,7",7)
2256B
2257"FRV1K",1130580001.101,"30,7",7,1)
2258MU STK-8 NUMER RS
2259"FRV1K",1130580001.101,"30,7",8)
2260B
2261"FRV1K",1130580001.101,"30,7",8,1)
2262MU STK-8 DENOM RS
2263"FRV1K",1130580001.101,"31,7",7)
2264B
2265"FRV1K",1130580001.101,"31,7",7,1)
2266MU STK-10 NUMER RS
2267"FRV1K",1130580001.101,"31,7",8)
2268B
2269"FRV1K",1130580001.101,"31,7",8,1)
2270MU STK-10 DENOM RS
2271"FRV1K",1130580001.101,"32,7",7)
2272B
2273"FRV1K",1130580001.101,"32,7",7,1)
2274MU VTE-1 NUMER RS
2275"FRV1K",1130580001.101,"32,7",8)
2276B
2277"FRV1K",1130580001.101,"32,7",8,1)
2278MU VTE-1 DENOM RS
2279"FRV1K",1130580001.101,"33,7",7)
2280B
2281"FRV1K",1130580001.101,"33,7",7,1)
2282MU VTE-2 NUMER RS
2283"FRV1K",1130580001.101,"33,7",8)
2284B
2285"FRV1K",1130580001.101,"33,7",8,1)
2286MU VTE-2 DENOM RS
2287"FRV1K",1130580001.101,"34,7",7)
2288B
2289"FRV1K",1130580001.101,"34,7",7,1)
2290MU VTE-3 NUMER RS
2291"FRV1K",1130580001.101,"34,7",8)
2292B
2293"FRV1K",1130580001.101,"34,7",8,1)
2294MU VTE-3 DENOM RS
2295"FRV1K",1130580001.101,"35,7",7)
2296B
2297"FRV1K",1130580001.101,"35,7",7,1)
2298MU VTE-4 NUMER RS
2299"FRV1K",1130580001.101,"35,7",8)
2300B
2301"FRV1K",1130580001.101,"35,7",8,1)
2302MU VTE-4 DENOM RS
2303"FRV1K",1130580001.101,"36,7",7)
2304B
2305"FRV1K",1130580001.101,"36,7",7,1)
2306MU VTE-5 NUMER RS
2307"FRV1K",1130580001.101,"36,7",8)
2308B
2309"FRV1K",1130580001.101,"36,7",8,1)
2310MU VTE-5 DENOM RS
2311"FRV1K",1130580001.101,"37,7",7)
2312B
2313"FRV1K",1130580001.101,"37,7",7,1)
2314MU VTE-6 NUMER RS
2315"FRV1K",1130580001.101,"37,7",8)
2316B
2317"FRV1K",1130580001.101,"37,7",8,1)
2318MU VTE-6 DENOM RS
2319"FRV1K",1130580001.101,"39,7",7)
2320B
2321"FRV1K",1130580001.101,"39,7",7,1)
2322MU NQF0421 BMI NUM ALL RS
2323"FRV1K",1130580001.101,"39,7",8)
2324B
2325"FRV1K",1130580001.101,"39,7",8,1)
2326MU NQF0421 BMI DENOM ALL RS
2327"FRV1K",1130580001.101,"39,7",9)
2328B
2329"FRV1K",1130580001.101,"39,7",9,1)
2330MU NQF0421 ADULT BMI
2331"FRV1K",1130580001.101,"40,7",7)
2332B
2333"FRV1K",1130580001.101,"40,7",7,1)
2334MU NQF0013 HTN NUMER2 RS
2335"FRV1K",1130580001.101,"40,7",8)
2336B
2337"FRV1K",1130580001.101,"40,7",8,1)
2338MU NQF0013 HTN DENOM2 RS
2339"FRV1K",1130580001.101,"41,7",7)
2340B
2341"FRV1K",1130580001.101,"41,7",7,1)
2342MU NQF0028A TOBACCO SCREEN NUM RS
2343"FRV1K",1130580001.101,"41,7",8)
2344B
2345"FRV1K",1130580001.101,"41,7",8,1)
2346MU NQF0028B TOBACCO INTERV DENOM RS
2347"FRV1K",1130580001.101,"42,7",7)
2348B
2349"FRV1K",1130580001.101,"42,7",7,1)
2350MU NQF0041 FLU RS
2351"FRV1K",1130580001.101,"42,7",8)
2352B
2353"FRV1K",1130580001.101,"42,7",8,1)
2354MU NQF0041 FLU DENOM RS
2355"FRV1K",1130580001.101,"43,7",7)
2356B
2357"FRV1K",1130580001.101,"43,7",7,1)
2358MU NQF0024 BMI 2-17YR NUM RS
2359"FRV1K",1130580001.101,"43,7",8)
2360B
2361"FRV1K",1130580001.101,"43,7",8,1)
2362MU NQF0024 BMI 2-17YRS DEM RS
2363"FRV1K",1130580001.101,"45,7",7)
2364B
2365"FRV1K",1130580001.101,"45,7",7,1)
2366MU NQF0059 HBA1C NUM RS
2367"FRV1K",1130580001.101,"45,7",8)
2368B
2369"FRV1K",1130580001.101,"45,7",8,1)
2370MU NQF0059 DM DENOM-ALL RS
2371"FRV1K",1130580001.101,"46,7",7)
2372B
2373"FRV1K",1130580001.101,"46,7",7,1)
2374MU NQF0064 NUM LDL RS
2375"FRV1K",1130580001.101,"46,7",8)
2376B
2377"FRV1K",1130580001.101,"46,7",8,1)
2378MU NQF0059 DM DENOM-ALL RS
2379"FRV1K",1130580001.101,"47,7",7)
2380B
2381"FRV1K",1130580001.101,"47,7",7,1)
2382MU NQF0061 NUM DM BP<140/90 RS
2383"FRV1K",1130580001.101,"47,7",8)
2384B
2385"FRV1K",1130580001.101,"47,7",8,1)
2386MU NQF0059 DM DENOM-ALL RS
2387"FRV1K",1130580001.101,"81,7",7)
2388B
2389"FRV1K",1130580001.101,"81,7",7,1)
2390MU NQF0028B TOBACCO INTERV NUM2 RS
2391"FRV1K",1130580001.101,"81,7",8)
2392B
2393"FRV1K",1130580001.101,"81,7",8,1)
2394MU NQF0028B TOBACCO INTERV DENOM RS
2395"FRV1K",1130580001.101,"82,7",7)
2396B
2397"FRV1K",1130580001.101,"82,7",7,1)
2398MU NQF0024 BMI PERCENTILE 2-10Y RS
2399"FRV1K",1130580001.101,"82,7",8)
2400B
2401"FRV1K",1130580001.101,"82,7",8,1)
2402MU NQF0024 BMI 2-10Y DENOM RS
2403"FRV1K",1130580001.101,"83,7",7)
2404B
2405"FRV1K",1130580001.101,"83,7",7,1)
2406MU NQF0038 NUM1 DPT RS
2407"FRV1K",1130580001.101,"83,7",8)
2408B
2409"FRV1K",1130580001.101,"83,7",8,1)
2410MU NQF0038 DENOM RS
2411"FRV1K",1130580001.101,"83,7",9)
2412B
2413"FRV1K",1130580001.101,"83,7",9,1)
2414MU NQF0038 CHILDREN'S IMMUNIZATIONS
2415"FRV1K",1130580001.101,"84,7",7)
2416B
2417"FRV1K",1130580001.101,"84,7",7,1)
2418MU NQF0038 NUM2 IPV RS
2419"FRV1K",1130580001.101,"84,7",8)
2420B
2421"FRV1K",1130580001.101,"84,7",8,1)
2422MU NQF0038 DENOM RS
2423"FRV1K",1130580001.101,"84,7",9)
2424B
2425"FRV1K",1130580001.101,"84,7",9,1)
2426MU NQF0038 CHILDREN'S IMMUNIZATIONS
2427"FRV1K",1130580001.101,"85,7",7)
2428B
2429"FRV1K",1130580001.101,"85,7",7,1)
2430MU NQF0038 NUM3-ALL RS
2431"FRV1K",1130580001.101,"85,7",8)
2432B
2433"FRV1K",1130580001.101,"85,7",8,1)
2434MU NQF0038 DENOM RS
2435"FRV1K",1130580001.101,"85,7",9)
2436B
2437"FRV1K",1130580001.101,"85,7",9,1)
2438MU NQF0038 CHILDREN'S IMMUNIZATIONS
2439"FRV1K",1130580001.101,"86,7",7)
2440B
2441"FRV1K",1130580001.101,"86,7",7,1)
2442MU NQF0038 NUM4 HIB RS
2443"FRV1K",1130580001.101,"86,7",8)
2444B
2445"FRV1K",1130580001.101,"86,7",8,1)
2446MU NQF0038 DENOM RS
2447"FRV1K",1130580001.101,"86,7",9)
2448B
2449"FRV1K",1130580001.101,"86,7",9,1)
2450MU NQF0038 CHILDREN'S IMMUNIZATIONS
2451"FRV1K",1130580001.101,"87,7",7)
2452B
2453"FRV1K",1130580001.101,"87,7",7,1)
2454MU NQF0038 NUM5 RS
2455"FRV1K",1130580001.101,"87,7",8)
2456B
2457"FRV1K",1130580001.101,"87,7",8,1)
2458MU NQF0038 DENOM RS
2459"FRV1K",1130580001.101,"87,7",9)
2460B
2461"FRV1K",1130580001.101,"87,7",9,1)
2462MU NQF0038 CHILDREN'S IMMUNIZATIONS
2463"FRV1K",1130580001.101,"88,7",7)
2464B
2465"FRV1K",1130580001.101,"88,7",7,1)
2466MU NQF0038 NUM6 VZV RS
2467"FRV1K",1130580001.101,"88,7",8)
2468B
2469"FRV1K",1130580001.101,"88,7",8,1)
2470MU NQF0038 DENOM RS
2471"FRV1K",1130580001.101,"88,7",9)
2472B
2473"FRV1K",1130580001.101,"88,7",9,1)
2474MU NQF0038 CHILDREN'S IMMUNIZATIONS
2475"FRV1K",1130580001.101,"89,7",7)
2476B
2477"FRV1K",1130580001.101,"89,7",7,1)
2478MU NQF0038 NUM7 PCV RS
2479"FRV1K",1130580001.101,"89,7",8)
2480B
2481"FRV1K",1130580001.101,"89,7",8,1)
2482MU NQF0038 DENOM RS
2483"FRV1K",1130580001.101,"89,7",9)
2484B
2485"FRV1K",1130580001.101,"89,7",9,1)
2486MU NQF0038 CHILDREN'S IMMUNIZATIONS
2487"FRV1K",1130580001.101,"90,7",7)
2488B
2489"FRV1K",1130580001.101,"90,7",7,1)
2490MU NQF0038 NUM8 HEP A RS
2491"FRV1K",1130580001.101,"90,7",8)
2492B
2493"FRV1K",1130580001.101,"90,7",8,1)
2494MU NQF0038 DENOM RS
2495"FRV1K",1130580001.101,"90,7",9)
2496B
2497"FRV1K",1130580001.101,"90,7",9,1)
2498MU NQF0038 CHILDREN'S IMMUNIZATIONS
2499"FRV1K",1130580001.101,"91,7",7)
2500B
2501"FRV1K",1130580001.101,"91,7",7,1)
2502MU NQF0038 NUM9 RV RS
2503"FRV1K",1130580001.101,"91,7",8)
2504B
2505"FRV1K",1130580001.101,"91,7",8,1)
2506MU NQF0038 DENOM RS
2507"FRV1K",1130580001.101,"91,7",9)
2508B
2509"FRV1K",1130580001.101,"91,7",9,1)
2510MU NQF0038 CHILDREN'S IMMUNIZATIONS
2511"FRV1K",1130580001.101,"92,7",7)
2512B
2513"FRV1K",1130580001.101,"92,7",7,1)
2514MU NQF0038 NUM10 INFLUENZA RS
2515"FRV1K",1130580001.101,"92,7",8)
2516B
2517"FRV1K",1130580001.101,"92,7",8,1)
2518MU NQF0038 DENOM RS
2519"FRV1K",1130580001.101,"92,7",9)
2520B
2521"FRV1K",1130580001.101,"92,7",9,1)
2522MU NQF0038 CHILDREN'S IMMUNIZATIONS
2523"FRV1K",1130580001.101,"93,7",7)
2524B
2525"FRV1K",1130580001.101,"93,7",7,1)
2526MU NQF0038 NUM11 COMBO5 RS
2527"FRV1K",1130580001.101,"93,7",8)
2528B
2529"FRV1K",1130580001.101,"93,7",8,1)
2530MU NQF0038 DENOM RS
2531"FRV1K",1130580001.101,"93,7",9)
2532B
2533"FRV1K",1130580001.101,"93,7",9,1)
2534MU NQF0038 CHILDREN'S IMMUNIZATIONS
2535"FRV1K",1130580001.101,"94,7",7)
2536B
2537"FRV1K",1130580001.101,"94,7",7,1)
2538MU NQF0038 NUM12 COMBO6 RS
2539"FRV1K",1130580001.101,"94,7",8)
2540B
2541"FRV1K",1130580001.101,"94,7",8,1)
2542MU NQF0038 DENOM RS
2543"FRV1K",1130580001.101,"94,7",9)
2544B
2545"FRV1K",1130580001.101,"94,7",9,1)
2546MU NQF0038 CHILDREN'S IMMUNIZATIONS
2547"IX",1130580001.101,1130580001.101,"MU",0)
25481130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
2549"IX",1130580001.101,1130580001.101,"MU",1)
2550S ^C0Q(101,"MU",$E(X,1,30),DA)=""
2551"IX",1130580001.101,1130580001.101,"MU",2)
2552K ^C0Q(101,"MU",$E(X,1,30),DA)
2553"IX",1130580001.101,1130580001.101,"MU",2.5)
2554K ^C0Q(101,"MU")
2555"IX",1130580001.101,1130580001.101,"MU",11.1,0)
2556^.114IA^1^1
2557"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
25581^F^1130580001.101^.3^30^1^F
2559"MBREQ")
25600
2561"PGL",1130580001.101,0,2,1)
2562NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2563"PGL",1130580001.101,0,3,2)
2564DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2565"PGL",1130580001.101,7,2,1.1)
2566ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2567"PGL",1130580001.101,7,3,2.1)
2568ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2569"PGL",1130580001.101,7,4,1.5)
2570NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2571"PGL",1130580001.101,7,5,1.51)
2572ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2573"PGL",1130580001.101,7,7,1.2)
2574NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2575"PGL",1130580001.101,7,8,2.2)
2576DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2577"PGL",1130580001.101,7,9,2.5)
2578EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2579"PKG",215,-1)
25801^1
2581"PKG",215,0)
2582QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
2583"PKG",215,20,0)
2584^9.402P^^
2585"PKG",215,22,0)
2586^9.49I^1^1
2587"PKG",215,22,1,0)
25881.0^3120731^3120802^8
2589"PKG",215,22,1,"PAH",1,0)
25903^3120803
2591"PKG",215,22,1,"PAH",1,1,0)
2592^^155^155^3120803
2593"PKG",215,22,1,"PAH",1,1,1,0)
2594 Summary
2595"PKG",215,22,1,"PAH",1,1,2,0)
2596 =======
2597"PKG",215,22,1,"PAH",1,1,3,0)
2598 This build contains the Quality Measures file (#1130580001.101) fully
2599"PKG",215,22,1,"PAH",1,1,4,0)
2600 populated with the Reminder Rule Sets and if applicable Reminder Extract
2601"PKG",215,22,1,"PAH",1,1,5,0)
2602 definitions for use with the Quality Measures package for reporting for
2603"PKG",215,22,1,"PAH",1,1,6,0)
2604 Meaningful use Stage I.
2605"PKG",215,22,1,"PAH",1,1,7,0)
2606
2607"PKG",215,22,1,"PAH",1,1,8,0)
2608 Source, Copyright, & Licensing:
2609"PKG",215,22,1,"PAH",1,1,9,0)
2610 ===============================
2611"PKG",215,22,1,"PAH",1,1,10,0)
2612 This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew
2613"PKG",215,22,1,"PAH",1,1,11,0)
2614Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0
2615"PKG",215,22,1,"PAH",1,1,12,0)
2616patches 12 and 17. The build was produced in July 2012.
2617"PKG",215,22,1,"PAH",1,1,13,0)
2618 Copyright WorldVistA 2012.
2619"PKG",215,22,1,"PAH",1,1,14,0)
2620 Licensed under GPL version 2 or later. Find it here:
2621"PKG",215,22,1,"PAH",1,1,15,0)
2622http://www.gnu.org/licenses/gpl-2.0.html
2623"PKG",215,22,1,"PAH",1,1,16,0)
2624 Released through VISTA Forum.
2625"PKG",215,22,1,"PAH",1,1,17,0)
2626
2627"PKG",215,22,1,"PAH",1,1,18,0)
2628 Functionality:
2629"PKG",215,22,1,"PAH",1,1,19,0)
2630 ==============
2631"PKG",215,22,1,"PAH",1,1,20,0)
2632 This patch is a pure data patch. It only installs reference data in the
2633"PKG",215,22,1,"PAH",1,1,21,0)
2634C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package
2635"PKG",215,22,1,"PAH",1,1,22,0)
2636data (specifically rule sets and extracts) sent in C0Q*1.0*2.
2637"PKG",215,22,1,"PAH",1,1,23,0)
2638
2639"PKG",215,22,1,"PAH",1,1,24,0)
2640 Package Elements:
2641"PKG",215,22,1,"PAH",1,1,25,0)
2642 =================
2643"PKG",215,22,1,"PAH",1,1,26,0)
2644 This build transports entries in the C0Q QUALITY MEASURE file.
2645"PKG",215,22,1,"PAH",1,1,27,0)
2646
2647"PKG",215,22,1,"PAH",1,1,28,0)
2648 Routines:
2649"PKG",215,22,1,"PAH",1,1,29,0)
2650 =========
2651"PKG",215,22,1,"PAH",1,1,30,0)
2652 <None>
2653"PKG",215,22,1,"PAH",1,1,31,0)
2654
2655"PKG",215,22,1,"PAH",1,1,32,0)
2656 Documentation:
2657"PKG",215,22,1,"PAH",1,1,33,0)
2658 <None besides this KIDS description>
2659"PKG",215,22,1,"PAH",1,1,34,0)
2660
2661"PKG",215,22,1,"PAH",1,1,35,0)
2662 Test Sites:
2663"PKG",215,22,1,"PAH",1,1,36,0)
2664 ===========
2665"PKG",215,22,1,"PAH",1,1,37,0)
2666 <None>
2667"PKG",215,22,1,"PAH",1,1,38,0)
2668
2669"PKG",215,22,1,"PAH",1,1,39,0)
2670 Compliance:
2671"PKG",215,22,1,"PAH",1,1,40,0)
2672 ===========
2673"PKG",215,22,1,"PAH",1,1,41,0)
2674 This software complies with the VA MUMPS Programming Standards and
2675"PKG",215,22,1,"PAH",1,1,42,0)
2676 Conventions (version 3 April 2007).
2677"PKG",215,22,1,"PAH",1,1,43,0)
2678
2679"PKG",215,22,1,"PAH",1,1,44,0)
2680 Installation Instructions:
2681"PKG",215,22,1,"PAH",1,1,45,0)
2682 ==========================
2683"PKG",215,22,1,"PAH",1,1,46,0)
2684 Pre-installation:
2685"PKG",215,22,1,"PAH",1,1,47,0)
2686
2687"PKG",215,22,1,"PAH",1,1,48,0)
2688 Prerequisite patches: (both found on the trac server here:
2689"PKG",215,22,1,"PAH",1,1,49,0)
2690 https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/)
2691"PKG",215,22,1,"PAH",1,1,50,0)
2692 C0Q*1.0*2
2693"PKG",215,22,1,"PAH",1,1,51,0)
2694 QUALITY MEASURES 1.0
2695"PKG",215,22,1,"PAH",1,1,52,0)
2696
2697"PKG",215,22,1,"PAH",1,1,53,0)
2698 Users can remain on the system while this patch is installed.
2699"PKG",215,22,1,"PAH",1,1,54,0)
2700
2701"PKG",215,22,1,"PAH",1,1,55,0)
2702 Install Time - less than 1 minute.
2703"PKG",215,22,1,"PAH",1,1,56,0)
2704
2705"PKG",215,22,1,"PAH",1,1,57,0)
2706 1. LOAD TRANSPORT GLOBAL
2707"PKG",215,22,1,"PAH",1,1,58,0)
2708
2709"PKG",215,22,1,"PAH",1,1,59,0)
2710 Choose the PackMan message containing this patch and invoke the
2711"PKG",215,22,1,"PAH",1,1,60,0)
2712 INSTALL/CHECK MESSAGE PackMan option to unload the build, or
2713"PKG",215,22,1,"PAH",1,1,61,0)
2714 Use the Load a Distribution option in KIDS to load it from a
2715"PKG",215,22,1,"PAH",1,1,62,0)
2716 host file.
2717"PKG",215,22,1,"PAH",1,1,63,0)
2718
2719"PKG",215,22,1,"PAH",1,1,64,0)
2720 2. START UP KIDS
2721"PKG",215,22,1,"PAH",1,1,65,0)
2722
2723"PKG",215,22,1,"PAH",1,1,66,0)
2724 Start up the Kernel Installation and Distribution System Menu
2725"PKG",215,22,1,"PAH",1,1,67,0)
2726 [XPD MAIN]:
2727"PKG",215,22,1,"PAH",1,1,68,0)
2728
2729"PKG",215,22,1,"PAH",1,1,69,0)
2730 Edits and Distribution ...
2731"PKG",215,22,1,"PAH",1,1,70,0)
2732 Utilities ...
2733"PKG",215,22,1,"PAH",1,1,71,0)
2734 Installation ...
2735"PKG",215,22,1,"PAH",1,1,72,0)
2736
2737"PKG",215,22,1,"PAH",1,1,73,0)
2738 Select Kernel Installation & Distribution System Option: INStallation
2739"PKG",215,22,1,"PAH",1,1,74,0)
2740 ---
2741"PKG",215,22,1,"PAH",1,1,75,0)
2742 Load a Distribution
2743"PKG",215,22,1,"PAH",1,1,76,0)
2744 Print Transport Global
2745"PKG",215,22,1,"PAH",1,1,77,0)
2746 Compare Transport Global to Current System
2747"PKG",215,22,1,"PAH",1,1,78,0)
2748 Verify Checksums in Transport Global
2749"PKG",215,22,1,"PAH",1,1,79,0)
2750 Install Package(s)
2751"PKG",215,22,1,"PAH",1,1,80,0)
2752 Restart Install of Package(s)
2753"PKG",215,22,1,"PAH",1,1,81,0)
2754 Unload a Distribution
2755"PKG",215,22,1,"PAH",1,1,82,0)
2756 Backup a Transport Global
2757"PKG",215,22,1,"PAH",1,1,83,0)
2758
2759"PKG",215,22,1,"PAH",1,1,84,0)
2760 Select Installation Option:
2761"PKG",215,22,1,"PAH",1,1,85,0)
2762
2763"PKG",215,22,1,"PAH",1,1,86,0)
2764 3. Select Installation Option:
2765"PKG",215,22,1,"PAH",1,1,87,0)
2766
2767"PKG",215,22,1,"PAH",1,1,88,0)
2768 NOTE: The following are OPTIONAL - (When prompted for the INSTALL
2769"PKG",215,22,1,"PAH",1,1,89,0)
2770 NAME, enter C0Q*1.0*3):
2771"PKG",215,22,1,"PAH",1,1,90,0)
2772
2773"PKG",215,22,1,"PAH",1,1,91,0)
2774 a. Backup a Transport Global - This option will create a backup
2775"PKG",215,22,1,"PAH",1,1,92,0)
2776 message of any routines exported with this patch. It will not
2777"PKG",215,22,1,"PAH",1,1,93,0)
2778 backup any other changes such as DD's or templates.
2779"PKG",215,22,1,"PAH",1,1,94,0)
2780 b. Compare Transport Global to Current System - This option will
2781"PKG",215,22,1,"PAH",1,1,95,0)
2782 allow you to view all changes that will be made when this patch
2783"PKG",215,22,1,"PAH",1,1,96,0)
2784 is installed. It compares all components of this patch
2785"PKG",215,22,1,"PAH",1,1,97,0)
2786 (routines, DD's, templates, etc.).
2787"PKG",215,22,1,"PAH",1,1,98,0)
2788 c. Verify Checksums in Transport Global - This option will allow
2789"PKG",215,22,1,"PAH",1,1,99,0)
2790 you to ensure the integrity of the routines that are in the
2791"PKG",215,22,1,"PAH",1,1,100,0)
2792 transport global.
2793"PKG",215,22,1,"PAH",1,1,101,0)
2794
2795"PKG",215,22,1,"PAH",1,1,102,0)
2796 4. Select Installation Option: Install Package(s)
2797"PKG",215,22,1,"PAH",1,1,103,0)
2798
2799"PKG",215,22,1,"PAH",1,1,104,0)
2800 **This is the step to start the installation of this KIDS patch:
2801"PKG",215,22,1,"PAH",1,1,105,0)
2802
2803"PKG",215,22,1,"PAH",1,1,106,0)
2804 a. Choose the Install Package(s) option to start the patch install
2805"PKG",215,22,1,"PAH",1,1,107,0)
2806 and enter "C0Q*1.0*3" at the INSTALL NAME prompt.
2807"PKG",215,22,1,"PAH",1,1,108,0)
2808 b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of
2809"PKG",215,22,1,"PAH",1,1,109,0)
2810 Install? NO//' answer NO
2811"PKG",215,22,1,"PAH",1,1,110,0)
2812 c. When prompted 'Want KIDS to INHIBIT LOGONs during the install?
2813"PKG",215,22,1,"PAH",1,1,111,0)
2814 NO//' answer NO
2815"PKG",215,22,1,"PAH",1,1,112,0)
2816 d. When prompted 'Want to DISABLE Scheduled Options, Menu Options,
2817"PKG",215,22,1,"PAH",1,1,113,0)
2818 and Protocols? NO//' answer NO
2819"PKG",215,22,1,"PAH",1,1,114,0)
2820
2821"PKG",215,22,1,"PAH",1,1,115,0)
2822
2823"PKG",215,22,1,"PAH",1,1,116,0)
2824Here is an example installation log.
2825"PKG",215,22,1,"PAH",1,1,117,0)
2826Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded
2827"PKG",215,22,1,"PAH",1,1,118,0)
2828from Di
2829"PKG",215,22,1,"PAH",1,1,119,0)
2830stribution 8/3/12@16:32:30
2831"PKG",215,22,1,"PAH",1,1,120,0)
2832 => SDFGHJKL ;Created on Aug 03, 2012@16:31:28
2833"PKG",215,22,1,"PAH",1,1,121,0)
2834
2835"PKG",215,22,1,"PAH",1,1,122,0)
2836This Distribution was loaded on Aug 03, 2012@16:32:30 with header of
2837"PKG",215,22,1,"PAH",1,1,123,0)
2838 SDFGHJKL ;Created on Aug 03, 2012@16:31:28
2839"PKG",215,22,1,"PAH",1,1,124,0)
2840 It consisted of the following Install(s):
2841"PKG",215,22,1,"PAH",1,1,125,0)
2842 C0Q*1.0*3
2843"PKG",215,22,1,"PAH",1,1,126,0)
2844
2845"PKG",215,22,1,"PAH",1,1,127,0)
2846 Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK
2847"PKG",215,22,1,"PAH",1,1,128,0)
2848 No overlap found
2849"PKG",215,22,1,"PAH",1,1,129,0)
2850DEVICE: HOME// PHOME HOME PRINTER
2851"PKG",215,22,1,"PAH",1,1,130,0)
2852
2853"PKG",215,22,1,"PAH",1,1,131,0)
2854
2855"PKG",215,22,1,"PAH",1,1,132,0)
2856 Install Started for C0Q*1.0*3 :
2857"PKG",215,22,1,"PAH",1,1,133,0)
2858 Aug 03, 2012@16:35:24
2859"PKG",215,22,1,"PAH",1,1,134,0)
2860
2861"PKG",215,22,1,"PAH",1,1,135,0)
2862Build Distribution Date: Aug 03, 2012
2863"PKG",215,22,1,"PAH",1,1,136,0)
2864
2865"PKG",215,22,1,"PAH",1,1,137,0)
2866 Installing Routines:.
2867"PKG",215,22,1,"PAH",1,1,138,0)
2868 Aug 03, 2012@16:35:24
2869"PKG",215,22,1,"PAH",1,1,139,0)
2870
2871"PKG",215,22,1,"PAH",1,1,140,0)
2872 Installing Data Dictionaries: ..
2873"PKG",215,22,1,"PAH",1,1,141,0)
2874 Aug 03, 2012@16:35:24
2875"PKG",215,22,1,"PAH",1,1,142,0)
2876
2877"PKG",215,22,1,"PAH",1,1,143,0)
2878 Installing Data:
2879"PKG",215,22,1,"PAH",1,1,144,0)
2880 Aug 03, 2012@16:35:24
2881"PKG",215,22,1,"PAH",1,1,145,0)
2882
2883"PKG",215,22,1,"PAH",1,1,146,0)
2884 Updating Routine file.....
2885"PKG",215,22,1,"PAH",1,1,147,0)
2886
2887"PKG",215,22,1,"PAH",1,1,148,0)
2888 Updating KIDS files.......
2889"PKG",215,22,1,"PAH",1,1,149,0)
2890
2891"PKG",215,22,1,"PAH",1,1,150,0)
2892 C0Q*1.0*3 Installed.
2893"PKG",215,22,1,"PAH",1,1,151,0)
2894 Aug 03, 2012@16:35:24
2895"PKG",215,22,1,"PAH",1,1,152,0)
2896
2897"PKG",215,22,1,"PAH",1,1,153,0)
2898 Not a VA primary domain
2899"PKG",215,22,1,"PAH",1,1,154,0)
2900
2901"PKG",215,22,1,"PAH",1,1,155,0)
2902 NO Install Message sent
2903"QUES","XPF1",0)
2904Y
2905"QUES","XPF1","??")
2906^D REP^XPDH
2907"QUES","XPF1","A")
2908Shall I write over your |FLAG| File
2909"QUES","XPF1","B")
2910YES
2911"QUES","XPF1","M")
2912D XPF1^XPDIQ
2913"QUES","XPF2",0)
2914Y
2915"QUES","XPF2","??")
2916^D DTA^XPDH
2917"QUES","XPF2","A")
2918Want my data |FLAG| yours
2919"QUES","XPF2","B")
2920YES
2921"QUES","XPF2","M")
2922D XPF2^XPDIQ
2923"QUES","XPI1",0)
2924YO
2925"QUES","XPI1","??")
2926^D INHIBIT^XPDH
2927"QUES","XPI1","A")
2928Want KIDS to INHIBIT LOGONs during the install
2929"QUES","XPI1","B")
2930NO
2931"QUES","XPI1","M")
2932D XPI1^XPDIQ
2933"QUES","XPM1",0)
2934PO^VA(200,:EM
2935"QUES","XPM1","??")
2936^D MG^XPDH
2937"QUES","XPM1","A")
2938Enter the Coordinator for Mail Group '|FLAG|'
2939"QUES","XPM1","B")
2940
2941"QUES","XPM1","M")
2942D XPM1^XPDIQ
2943"QUES","XPO1",0)
2944Y
2945"QUES","XPO1","??")
2946^D MENU^XPDH
2947"QUES","XPO1","A")
2948Want KIDS to Rebuild Menu Trees Upon Completion of Install
2949"QUES","XPO1","B")
2950NO
2951"QUES","XPO1","M")
2952D XPO1^XPDIQ
2953"QUES","XPZ1",0)
2954Y
2955"QUES","XPZ1","??")
2956^D OPT^XPDH
2957"QUES","XPZ1","A")
2958Want to DISABLE Scheduled Options, Menu Options, and Protocols
2959"QUES","XPZ1","B")
2960NO
2961"QUES","XPZ1","M")
2962D XPZ1^XPDIQ
2963"QUES","XPZ2",0)
2964Y
2965"QUES","XPZ2","??")
2966^D RTN^XPDH
2967"QUES","XPZ2","A")
2968Want to MOVE routines to other CPUs
2969"QUES","XPZ2","B")
2970NO
2971"QUES","XPZ2","M")
2972D XPZ2^XPDIQ
2973"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
2974
2975"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
2976@
2977"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
2978@
2979"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
2980@
2981"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
2982@
2983"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
2984@
2985"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
2986@
2987"VER")
29888.0^22.0
2989"^DD",1130580001.101,1130580001.101,0)
2990FIELD^^.3^18
2991"^DD",1130580001.101,1130580001.101,0,"DDA")
2992N
2993"^DD",1130580001.101,1130580001.101,0,"DT")
29943111201
2995"^DD",1130580001.101,1130580001.101,0,"ID",.7)
2996W:$D(^(5)) " ",$P(^(5),U,1)
2997"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
2998
2999"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
3000
3001"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
3002
3003"^DD",1130580001.101,1130580001.101,0,"VRPK")
3004QUALITY MEASURES
3005"^DD",1130580001.101,1130580001.101,.01,0)
3006NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
3007"^DD",1130580001.101,1130580001.101,.01,.1)
3008MEASURE NAME
3009"^DD",1130580001.101,1130580001.101,.01,1,0)
3010^.1
3011"^DD",1130580001.101,1130580001.101,.01,1,1,0)
30121130580001.101^B
3013"^DD",1130580001.101,1130580001.101,.01,1,1,1)
3014S ^C0Q(101,"B",$E(X,1,30),DA)=""
3015"^DD",1130580001.101,1130580001.101,.01,1,1,2)
3016K ^C0Q(101,"B",$E(X,1,30),DA)
3017"^DD",1130580001.101,1130580001.101,.01,3)
3018Answer must be 1-30 characters in length
3019"^DD",1130580001.101,1130580001.101,.01,"DT")
30203101012
3021"^DD",1130580001.101,1130580001.101,.3,0)
3022MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
3023"^DD",1130580001.101,1130580001.101,.3,.1)
3024MEANINGFUL USE YEAR KEY
3025"^DD",1130580001.101,1130580001.101,.3,3)
3026Answer must be 1-30 characters in length.
3027"^DD",1130580001.101,1130580001.101,.3,"DT")
30283111201
3029"^DD",1130580001.101,1130580001.101,.5,0)
3030TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
3031"^DD",1130580001.101,1130580001.101,.5,.1)
3032MEASURE TITLE
3033"^DD",1130580001.101,1130580001.101,.5,3)
3034Answer must be 3-240 characters in length
3035"^DD",1130580001.101,1130580001.101,.5,"DT")
30363110430
3037"^DD",1130580001.101,1130580001.101,.61,0)
3038VERY LONG DESCRIPTION^1130580001.111^^6;0
3039"^DD",1130580001.101,1130580001.101,.7,0)
3040DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
3041"^DD",1130580001.101,1130580001.101,.7,.1)
3042QRDA DISPLAY NAME
3043"^DD",1130580001.101,1130580001.101,.7,3)
3044Answer must be 3-240 characters in length
3045"^DD",1130580001.101,1130580001.101,.7,"DT")
30463101012
3047"^DD",1130580001.101,1130580001.101,.8,0)
3048REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
3049"^DD",1130580001.101,1130580001.101,.8,.1)
3050REPORTING MEASURE NAME
3051"^DD",1130580001.101,1130580001.101,.8,3)
3052Answer must be 3-30 characters in length
3053"^DD",1130580001.101,1130580001.101,.8,"DT")
30543110615
3055"^DD",1130580001.101,1130580001.101,1,0)
3056NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
3057"^DD",1130580001.101,1130580001.101,1,.1)
3058MEASURE NUMERATOR PATIENT LIST
3059"^DD",1130580001.101,1130580001.101,1,"DT")
30603101012
3061"^DD",1130580001.101,1130580001.101,1.1,0)
3062ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
3063"^DD",1130580001.101,1130580001.101,1.1,"DT")
30643110805
3065"^DD",1130580001.101,1130580001.101,1.2,0)
3066NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
3067"^DD",1130580001.101,1130580001.101,1.2,3)
3068Enter the reminder rule set to use for this measure.
3069"^DD",1130580001.101,1130580001.101,1.2,12)
3070If the type of the reminder list rule is a Rule Set.
3071"^DD",1130580001.101,1130580001.101,1.2,12.1)
3072S DIC("S")="I $P(^(0),U,3)=3"
3073"^DD",1130580001.101,1130580001.101,1.2,21,0)
3074^^5^5^3120716^
3075"^DD",1130580001.101,1130580001.101,1.2,21,1,0)
3076This is the numerator reminder rule set to use for the quality measure.
3077"^DD",1130580001.101,1130580001.101,1.2,21,2,0)
3078
3079"^DD",1130580001.101,1130580001.101,1.2,21,3,0)
3080The rule set is used to generate a patient list, which this package
3081"^DD",1130580001.101,1130580001.101,1.2,21,4,0)
3082referneces. The contents of the patient list will produce the count for
3083"^DD",1130580001.101,1130580001.101,1.2,21,5,0)
3084the measure. This count is for the numerator.
3085"^DD",1130580001.101,1130580001.101,1.2,"DT")
30863120716
3087"^DD",1130580001.101,1130580001.101,1.5,0)
3088NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
3089"^DD",1130580001.101,1130580001.101,1.5,.1)
3090LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
3091"^DD",1130580001.101,1130580001.101,1.5,"DT")
30923110809
3093"^DD",1130580001.101,1130580001.101,1.51,0)
3094ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
3095"^DD",1130580001.101,1130580001.101,1.51,.1)
3096NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
3097"^DD",1130580001.101,1130580001.101,1.51,"DT")
30983110809
3099"^DD",1130580001.101,1130580001.101,2,0)
3100DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
3101"^DD",1130580001.101,1130580001.101,2,.1)
3102MEASURE DENOMINATOR PATIENT LIST
3103"^DD",1130580001.101,1130580001.101,2,"DT")
31043101012
3105"^DD",1130580001.101,1130580001.101,2.1,0)
3106ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
3107"^DD",1130580001.101,1130580001.101,2.1,"DT")
31083110805
3109"^DD",1130580001.101,1130580001.101,2.2,0)
3110DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
3111"^DD",1130580001.101,1130580001.101,2.2,3)
3112Enter the reminder rule set to use for this measure.
3113"^DD",1130580001.101,1130580001.101,2.2,12)
3114If the type of the reminder list rule is a Rule Set.
3115"^DD",1130580001.101,1130580001.101,2.2,12.1)
3116S DIC("S")="I $P(^(0),U,3)=3"
3117"^DD",1130580001.101,1130580001.101,2.2,21,0)
3118^^5^5^3120716^
3119"^DD",1130580001.101,1130580001.101,2.2,21,1,0)
3120This is the denominator reminder rule set to use for the quality measure.
3121"^DD",1130580001.101,1130580001.101,2.2,21,2,0)
3122
3123"^DD",1130580001.101,1130580001.101,2.2,21,3,0)
3124The rule set is used to generate a patient list, which this package
3125"^DD",1130580001.101,1130580001.101,2.2,21,4,0)
3126referneces. The contents of the patient list will produce the count for
3127"^DD",1130580001.101,1130580001.101,2.2,21,5,0)
3128the measure. This count is for the denominator.
3129"^DD",1130580001.101,1130580001.101,2.2,"DT")
31303120716
3131"^DD",1130580001.101,1130580001.101,2.5,0)
3132EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
3133"^DD",1130580001.101,1130580001.101,2.5,3)
3134Select a Reminder Extract Definition for this measure
3135"^DD",1130580001.101,1130580001.101,2.5,21,0)
3136^^4^4^3120726^
3137"^DD",1130580001.101,1130580001.101,2.5,21,1,0)
3138If this measure depends upon a reminder extract definition, you can add
3139"^DD",1130580001.101,1130580001.101,2.5,21,2,0)
3140this extract definition here. This will alter how the Quality Measures
3141"^DD",1130580001.101,1130580001.101,2.5,21,3,0)
3142package computes the measure to use the extract in addition and prior to
3143"^DD",1130580001.101,1130580001.101,2.5,21,4,0)
3144the rule sets.
3145"^DD",1130580001.101,1130580001.101,2.5,"DT")
31463120726
3147"^DD",1130580001.101,1130580001.101,3,0)
3148QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
3149"^DD",1130580001.101,1130580001.101,3,.1)
3150MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
3151"^DD",1130580001.101,1130580001.101,3,3)
3152Answer must be 3-120 characters in length
3153"^DD",1130580001.101,1130580001.101,3,"DT")
31543101012
3155"^DD",1130580001.101,1130580001.101,3.1,0)
3156QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
3157"^DD",1130580001.101,1130580001.101,3.1,.1)
3158QRDA SYSTEM OID (FIXED)
3159"^DD",1130580001.101,1130580001.101,3.1,9.01)
3160
3161"^DD",1130580001.101,1130580001.101,3.1,9.1)
3162S X="2.16.840.1.113883.3.249.12"
3163"^DD",1130580001.101,1130580001.101,3.1,"DT")
31643101012
3165"^DD",1130580001.101,1130580001.101,3.2,0)
3166QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
3167"^DD",1130580001.101,1130580001.101,3.2,.1)
3168QRDA MEASURE CODE
3169"^DD",1130580001.101,1130580001.101,3.2,3)
3170Answer must be 1-80 characters in length
3171"^DD",1130580001.101,1130580001.101,3.2,"DT")
31723101012
3173"^DD",1130580001.101,1130580001.111,0)
3174VERY LONG DESCRIPTION SUB-FIELD^^.01^1
3175"^DD",1130580001.101,1130580001.111,0,"DT")
31763101013
3177"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
3178
3179"^DD",1130580001.101,1130580001.111,0,"UP")
31801130580001.101
3181"^DD",1130580001.101,1130580001.111,.01,0)
3182VERY LONG DESCRIPTION^Wx^^0;1
3183"^DD",1130580001.101,1130580001.111,.01,.1)
3184LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
3185"^DD",1130580001.101,1130580001.111,.01,3)
3186LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
3187"^DD",1130580001.101,1130580001.111,.01,"DT")
31883101013
3189"^DIC",1130580001.101,1130580001.101,0)
3190C0Q QUALITY MEASURE^1130580001.101
3191"^DIC",1130580001.101,1130580001.101,0,"GL")
3192^C0Q(101,
3193"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
3194
3195**END**
3196**END**
Note: See TracBrowser for help on using the repository browser.